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Cells employ signaling pathways to make decisions in response to changes in 
their immediate environment. Transforming Growth Factor β (TGFβ) signaling 
pathway plays pivotal roles in regulating many cellular processes, including cell 
proliferation, differentiation and migrations. Although the principal components 
of TGFβ signaling have been identified and explored in recent decades, 
understanding its dynamic behavior is limited by the lack of tools that allow the 
control of TGFβ signaling at high spatiotemporal resolution. In this thesis, we 
developed an optogenetic system (the optoTGFβ system), in which light is used 
to control TGFβ signaling precisely in time and space. First, we validated the 
functionality of the optoTGFβ system by comparing it with the endogenous 
TGFβ signaling system. Second, by simultaneously monitoring the subcellular 
translocation of the receptors and Smad proteins using live cell imaging, we 
showed that TGFβ signaling can be specifically activated in single cells through 
modulating the light stimulations. Third, in combination with mathematical 
modeling, we quantitatively characterized the dynamics of TGFβ signaling in the 
optoTGFβ system. The spatial and temporal precision of optical control makes 
the optoTGFβ system a novel and powerful tool for quantitative analyses and 
manipulation of TGFβ signaling at the single cell level. 
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II 
 
 
 
Zellen benutzen Signalwege ein, um auf Änderungen in ihrer unmittelbaren 
Umgebung zu reagieren. Der Signalweg des transformierenden 
Wachstumsfaktors β (TGFβ) spielt eine entscheidende Rolle bei der Regulierung 
vieler zellulärer Prozesse, einschließlich Zellproliferation, Differenzierung und 
Migration. Obwohl die Hauptkomponenten der TGFβ-Signalgebung in den 
letzten Jahrzehnten identifiziert und erforscht wurden, ist das Verständnis ihres 
dynamischen Verhaltens durch das Fehlen von Methoden eingeschränkt, die die 
Steuerung der TGFβ-Signalgebung mit hoher räumlicher und zeitlicher 
Auflösung ermöglichen. In dieser Arbeit wurde ein optogenetisches System (das 
optoTGFβ-System) entwickelt, bei dem Licht dazu verwendet wird, die TGFβ-
Signalgebung zeitlich und räumlich präzise zu steuern. Erstens wurde die 
Funktionalität des optoTGFβ-Systems durch Vergleich mit dem endogenen 
TGFβ-Signalsystem überprüft. Zweitens wurde durch das gleichzeitige 
Überwachen der subzellulären Translokation der Rezeptoren und der Smad-
Proteine mittels „Live Cell Imaging“ gezeigt, dass die TGFβ-Signalgebung durch 
Modulation der Lichtstimulationen in einzelnen Zellen spezifisch aktiviert 
werden kann. Drittens wurde in Kombination mit der mathematischen 
Modellierung die Dynamik der TGFβ-Signalgebung im optoTGFβ-System 
quantitativ bestimmt. Die räumliche und zeitliche Präzision der optischen 
Kontrolle machen das optoTGFβ-System zu einem neuartigen und 
leistungsfähigen Methode für die quantitative Analyse und Manipulation von 
TGFβ-Signalen auf Einzelzellebene. 
 
Schlagwörter:   
optogenetik, Signaltransduktion, TGFβ, raumzeitliche Präzision, 
Mathematische Modellierung 
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Life, as an amazing existence that feeds on negative entropy in a universe with 
unavoidably increasing entropy, has to communicate with its environment 
constantly. As the basic building blocks of life, cell has to perceive, make sense 
and respond to its environment, which is implemented by a variety of signaling 
pathways. Among them, TGFβ signaling is one of the highly conserved and 
crucial signaling pathways for various cellular processes such as cell proliferation 
and migration. 
As the ultimate source of energy for life, light is not only powering biological 
processes, but could also modulate them via a series of photosensitive proteins. 
With the development of synthetic biology and optogenetics, researchers 
harnessed these light-modulated proteins to create artificial photosensitive 
proteins for modulating a wider range of cellular processes. Due to its 
convenience and high spatiotemporal resolution, optogenetics is a powerful 
approach to study and control cellular activities. 
In this chapter, I first introduced the general principles of signaling pathways. 
Then focusing on the TGFβ signaling, I introduced its major components, core 
molecular mechanisms, and some other properties. Later on, I introduced two 
sets of optogenetic toolkits: one is for modulating membrane voltage potential; 
the other is for modulating cell signaling. We mainly focused on the later one, 
from which we would select proper tools for manipulating TGFβ signaling in the 
following chapters. 
1 
Introduction 
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Cells are the basic element for most organisms. On the one hand, cells have to 
perceive and respond to the surrounding signals correctly for successful survival. 
On the other hand, an organic body, or a microbial community has to employ 
multiple signals to govern and coordinate the corresponding cells efficiently for 
its proper development. Defects or deviation in signal perception or information 
processing are related to common diseases such as heart disease, cancer, diabetes 
and Alzheimer's disease. 
At the molecular level, there exists a series of biochemical processes that 
transmit the signal from the starting point of signal perceiving, to the end point 
of cellular response. Commonly we call this series of molecular events as 
signaling transduction or signaling pathway. There are mainly three stages 
(Figure 1.1.1) in the signaling transduction in which various molecular 
components are involved in specific biochemical reactions: signal perception, 
intracellular signal transmission and cellular response.  
 
Figure 1.1.1 Signaling transduction. The three main stages in signaling 
transduction: signal perception by receptors, which translates the signal into a 
biochemical signal; intracellular signal transmission by a series of molecular events that 
relay the signal; cellar response such as gene expression, or metabolism alternation. 
  
The signal perception stage involves the detection of a specific stimulus, and 
translates it into a biochemical signal. The stimuli could range from physical 
signals (e.g. mechanical forces1, osmolarity2, temperature3, light4) to chemical 
signals, commonly known as ligands, which constitute the majority of the stimuli. 
The second stage of signaling transduction consists of a series of molecular 
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events that relay or process the signal, including protein translocation, allosteric 
regulation, protein phosphorylation, other posttranslational modifications 
(methylation, acetylation) and so on. The last stage of signaling transduction is 
the cellular response such as gene expression5, protein degradation6 or 
metabolism alteration7. 
Cell signaling involves multiple processes in which various regulators and 
effectors participate and form networks. Therefore, traditional approaches in 
biological researches focusing on individual parts of the signaling pathways are 
not sufficient to fully understand them. Systems biology provides us with a 
theoretical tool to analyze the underlying structure as well as the spatiotemporal 
dynamics of the cell signaling networks. Through combining experimental 
approaches with theoretical analysis, we could not only better characterize the 
cell signaling, but also modulate it effectively for therapeutic purposes.  
There are numerous signaling pathways in the cells (Figure 1.1.2), for instance, 
MAPK/ERK signaling pathway is well-known for its regulation on cell cycle 
entry and proliferation8, PI3K/Akt/mTOR signaling pathway for its modulation 
on cell proliferation and differentiation9, JAK-STAT signaling pathway for its 
regulation on immunity and development10, etc.  
 
Figure 1.1.2 Signaling pathways.  Numerous cell signaling pathways exist in the 
cells. These signaling circuits transmit extracellular signals as well as intracellular signals 
to regulate cellular activities and cell fate. This figure is adapted, modified from 
Hanahan et al. (2000)11. 
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 β
Among the diverse signaling pathways, the transforming growth factor beta 
(TGFβ) signaling pathway plays an important role in various cellular processes 
including cell proliferation, differentiation and migration (Figure 1.2.1)12. 
Accordingly, malfunctions of TGFβ signaling have been connected to a variety of 
disease such as atherosclerosis, cancer, developmental defects 13, reproductive 
disorders, and connective tissue diseases14. 
 
Figure 1.2.1 Functions of TGFβ signaling.  TGFβ signaling plays a crucial role 
in multiple cellular processes such as cell proliferation, cell differentiation, tissue 
development, cell migration and homeostasis.  
 
Although the functions of TGFβ signaling are versatile, the core molecular 
mechanism of the canonical signaling transduction is relatively simple (Figure 
1.2.2). Briefly, a dimeric ligand (the active form)15 induces the assembly of two 
type I receptors and two type II receptors to form a symmetric 2:2:2 complex 
(ligand-receptor-complex, LRC). The oligomerization of the receptors promotes 
activation of the type I receptor through transphosphorylation, catalyzed by the 
constitutively active kinase of the type II receptor16. In the canonical TGFβ 
signaling, the activated kinase domain of the type I receptor phosphorylates the 
receptor-regulated Smad proteins (R-Smads, i.e., Smad2 and Smad3 for TGFβ-
like signaling pathway; Smad1, Smad5 and Smad8 for BMP-like signaling 
pathway) 17. The R-Smads then bind to the common mediator Smad4 (co-Smad) 
and translocate into the nucleus18. There, these phosphorylated R-Smads/co-
Smad complexes bind to DNA in conjunction with other transcription 
factors/cofactors, regulating the transcription of various target genes19,20. 
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Figure 1.2.2 Molecular mechanism of TGFβ signaling.  A pair of TGFβ ligands 
form a dimer and bind to the extracellular domains of a pair of type II receptors, which 
then recruit and phosphorylate a pair of type I receptors. The activated type I receptors 
then phosphorylate the R-Smads (receptor-regulated Smads), which together with the 
co-Smad (Smad4) translocate into the nucleus and regulate the transcription of multiple 
target genes. 
 
The TGFβ superfamily is a large group of structurally-related growth factors 
which is conserved and developed throughout metazoan evolution. According to 
their sequence similarity as well as functionality, these cytokines are divided into 
two major groups: TGFβ-like group and BMP (Bone Morphogenetic Proteins)-
like group. The TGFβ-like group includes TGFβs, Nodals, Activins and a few 
GDFs (Growth and Differentiation Factors). The BMP-like group contains BMPs, 
AMH (Anti-Müllerian hormone) and most GDFs21. The TGFβ family signaling 
pathways emerged at the onset of metazoan life and evolved rapidly to higher 
degrees of complexity22. Caenorhabditis elegans express five TGFβ related ligands, 
including the BMP-like DBL-1, the TGFβ-like DAF-7 and three yet unexplored 
ligands: UNC-129, TIG-2 and TIG-3. Drosophila melanogaster expresses seven 
TGFβ family ligands, including BMP-like Dpp (Decapentaplegic), Scw (Screw) 
and Gbb (Glass bottom boat), regulating patterning and differentiation; TGFβ-
like dActivin and Daw (Dawdle), regulating tissue-specific events; and other less 
understood members. Xenopus laevis expresses TGFβs, Activins, Nodals, Activins, 
GDFs and BMPs23 as well as some unique members such as XNR1-624 and 
Derrière25. Consistent with the increasing anatomical complexity and new 
functionality, mammalian genomes encode over 30 TGFβ family ligands for 
various fundamental cellular processes. 
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Figure 1.2.3 Schematic illustration of the specific binding between TGFβ 
ligands and TGFβ receptors.  RI, type I receptor; RII, type II receptor. In red color, 
TGFβ-like pathway members; in blue color, BMP-like pathway members. This figure is 
adapted, modified from Heldin et al. (2016)26. 
 
In accordance with the TGFβ ligand family, there is a TGFβ receptor family. 
However, in contrast to the large family of TGFβ ligands, the TGFβ receptor 
family is relatively small, with only 12 members in mammals, including seven 
type I receptors and five type II receptors in human. The TGFβ signaling is 
initiated by the assembly of a LRC comprised of one pair of TGFβ ligand binding 
to a pair of type I receptors and a pair of type II receptors. Each TGFβ ligand 
family member binds to specific combinations of type I and type II receptors, and 
each receptor is shared by several TGFβ ligand family members (Figure 1.2.3). 
Receptors in this family are dual specificity kinases, and have structural 
characteristics similar to both tyrosine kinases and serine/threonine kinase27. 
Generally, the type II TGFβ receptors have higher affinities for the ligands than 
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the type I TGFβ receptors28, whereas type I BMP receptors have higher affinities 
for the ligands than the type II BMP receptors29. 
Among the members of the TGFβ superfamily, TGFβ1 is the first identified 
one. Later on, TGFβ2 and TGFβ3 have been identified as another two isoforms. 
Members of this TGFβ subfamily and their receptors have been better 
characterized compared with other subfamilies. In this study, we zoom in and 
focus on the TGFβ subfamily signaling. 
 
 β
 β
The biologically active form of TGFβ ligand is characterized by a homodimer 
that is stabilized by hydrophobic interactions and a covalent disulfide bond. In 
each monomer, three highly conserved intra-molecular disulfide bonds form a 
tight structure termed the ‘cystine knot’, interlocking the extended beta strands in 
the ligands30. The mature and dimeric form of TGFβ ligand is released from a 
precursor protein, which contains a large amino-terminus prodomain for correct 
folding31. 
The activity of TGFβ ligands is determined by several aspects. Firstly, different 
ligand isoforms differ in their affinities to the receptors. For instance, TGFβ2 
shows lower affinity than TGFβ1 and TGFβ3 to TβRII32. Secondly, various 
extracellular ligand-binding proteins regulate the TGFβ ligands access to the 
receptors. For instance, ligand-trapping proteins such as LAP (latency-associated 
polypeptide) and α2-macroglobulin, sequester the ligands from their 
corresponding receptors33,34; mediators such as LTBP1 (latent TGFβ-binding 
protein 1) could mediate interactions with integrin receptors to release the 
mature ligands from the traps35,36 
 
 β
The TGFβ receptors comprise a small cysteine-rich extracellular domain, a 
transmembrane domain, a juxta-membrane domain and a kinase domain. 
Compared with BMP type II receptor and most tyrosine kinase receptors, the 
carboxyl-terminus of their kinase domains are relatively shorter. The 
extracellular domains of the TGFβ receptors are responsible for the recognition of 
the ligands, which facilitates formation of LRC and initiates the signaling. 
Glycosylation on the extracellular domains regulates TGFβ receptor activity 
through determining its sensitivity to the ligands, and affecting internalization 
and cell-surface transportation of the receptors 37-39. 
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Figure 1.2.4 Schematic diagram of the structural/functional characteristics 
of TβRI and TβRII.  The TGFβ receptors are composed of four major structural motifs: 
an extracellular domain, a transmembrane domain, a juxta-membrane domain and a 
kinase domain. The L45 loop on TβRI is the epitope for its specific recognition of Smads.  
The motif between L529 and F538 in TβRII is responsible for its delivery to the 
basolateral side of the polarized epithelial cells. Phosphorylation sites, post-
translationally modifies residues and functional motifs are indicated. White circles with 
‘Gly’, N-linked glycosylations; yellow circles with ‘P’, phosphorylation sites; black circles 
with ‘Ub’, ubiquitins; blue circles with ‘Su’, SUMO groups; red circles with ‘Ne’, NEDD8 
moleculrs. ‘+’ and ‘-’ beside the phosphorylation sites indicate positive and negative 
impact of phosphorylation on the kinase activity. ‘Src’ beside the Y284 and Y470, the 
sites phosphorylated by Src, in contrast to other auto-phosphorylation sites on TβRII. 
‘Auto’ beside Y470, indicating it could be also auto-phosphorylated. N, amino terminus; 
C, carboxyl-terminus. This figure is adapted, modified from Heldin et al. (2016)26. 
 
The activity of the TGFβ receptors is mainly regulated by phosphorylation, 
post-translationally modification and other functional motifs in their cytoplasmic 
region (Figure 1.2.4).  
TβRII is constitutively active and its kinase activity is regulated by auto-
phosphorylation at several serine and tyrosine residues, including Ser213, Ser409, 
Ser416, Tyr259, Tyr336, Tyr424 and Tyr47040,41. Among them, phosphorylation at 
Ser213 or Ser409 promotes its kinase activity, while phosphorylation at Ser416 
inhibits its activity40. In addition, TβRII can also be phosphorylated by Src at 
Tyr284 and Tyr470 for regulation of various responses42,43. TCPTP (the T cell 
protein tyrosine phosphatase) has been shown to dephosphorylate TβRII tail 
tyrosine residues, inhibiting TβRs dependent fibrotic signaling44. 
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The activity of TβRI is mainly regulated by phosphorylation of the residues in 
its GS domain, which is promoted by the ligand-induced approximation between 
the homodimers of TβRI and TβRII. The phosphorylation of TβRI on the one 
hand results in a conformational transformation, which relieves the kinase from 
the binding of the inhibitor FKBP12 (FK506-binding protein), and on the other 
hand, facilitates its interaction with the R-Smads45-47. Residues in the GS domain 
that are phosphorylated by TβRII include Ser187, Ser189, Ser191 and Thr186, 
which reside just upstream of the kinase domain48. Although none of these 
residues is crucial for TβRI kinase activation, phosphorylation level in this region 
needs to reach a certain threshold for the activation. Besides the phosphorylation 
in the GS domain, TGFβ signaling could also be modulated by phosphorylation 
at Ser165 in the juxamembrane area49. Phosphatase such as PP1 (protein 
phosphatase 1) could dephosphorylate TβRI by binding to Smad7 and thus being 
recruited to the receptor50. Another phosphatase PP2A (protein phosphatase 2A) 
regulates the receptors reciprocally through the two isoforms of its regulatory 
subunit B: while Bα (PPP2R2A) stabilizes the TβRI and enhances signaling, Bδ 
(PPP2R2D) restricts the receptor activity51,52. 
Besides phosphorylation, other layers of regulation exist for TGFβ receptors, 
which are implemented by ubiquitylation, deubiquitylation, sumoylation and 
neddylation. The stability of the TGFβ receptors is controlled by the balance 
between polyubiquitylation and deubibiquitylation, although the exact residues 
that are modified haven’t been identified yet. The E3 ligases of the Smurf (Smad 
ubiquitination related factor) family have been shown to enhance the turnover of 
TβRI through Smad7, which plays as a negative feedback for tightly regulating 
the TGFβ signaling53,54. Several deubiquitylases such as USP4 (ubiquitin specific 
protease), USP15 and USP11 have been identified for deubiquitylating TβRI and 
thus promoting the TGFβ signaling55-57.  
The amino acid residue Lys389 in the kinase domain of TβRI participates in 
signaling by sumoylation, which promotes Smads phosphorylation. The 
sumoylation process is further regulated by a nearby residue Ser38758,59. Two 
residues (Lys556 and Lys567) downstream of the kinase domain of TβRII could 
be modified by NEDD8 (neural precursor cell expressed, developmentally down-
regulated 8), which is an ubiquitin-like molecule. This inhibits the degradation of 
TβRII through preventing its endocytosis to caveolin-positive compartments, 
while promoting its endocytosis to early endosomes60. In addition, an 
LTAxxVAxxF motif at the end of the TβRII kinase domain ensures its proper 
delivery to the basolateral membrane61. 
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Smad family proteins mediate TGFβ signaling from the trans-membrane 
receptors to the nucleus. According to their structural and functional 
characteristics, members of the Smad family are divided into three classes: R-
Smad (Receptor-regulated Smad), Co-Smad (Common mediator Smad) and I-
Smad (Inhibitory Smad). R-Smads directly associate with and are activated by 
type I receptors. The activated R-Smads then form heteromeric complexes with 
Co-Smads and shuttle into the nucleus to regulate target gene transcription. I-
Smads are transcriptionally induced by TGFβ ligands and negatively regulate 
TGFβ signaling via a variety of mechanisms. For example, through binding to the 
type I receptors, I-Smads not only block the association and phosphorylation of 
R-Smads, but also recruit PP1 (protein phosphatase 1) or Smurfs to 
dephosphorylate or degrade the receptors, respectively. Moreover, I-Smads also 
disrupt the formation of Smads-DNA complex, and engage HDACs (Histone 
deacetylases) to repress transcription in the nucleus50,62-64. 
 
Figure 1.2.5 Schematic illustration of the Smads architecture. The three 
functional classes of the Smad family: R-Smads, direct phosphorylation target of 
activated type I receptors (A); Co-Smad, the common mediator, could bind to various R-
Smads (B); I-Smads, negative regulators of the TGFβ signaling (C). βH, the β-hairpin 
domain. PPXY, the proline-tyrosine motif. L3, the L3 loop. SXS, the C-terminus SXS 
motif. NLS, nuclear localization signal. NES, nuclear export signal. Ex3, the exon 3 of 
Smad2. SAD, the Smad4 activation domain. ‘Sumo’ with red triangle, sumoylation site. 
‘Ub’ with red triangle, ubiquitylation site. ‘Me’ with red triangle, methylation site. ‘Ac’ 
with red triangle, acetylation site. This figure is adapted, modified from Moustakas et al. 
(2009)65. 
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The architectures of all the R-Smads and Co-Smads are similar: a conserved 
MH1 (Mad Homology 1) domain at the N-terminus, a conserved MH2 domain at 
the C-ternimus, and a linker domain connecting them (Figure 1.2.5 A, B). The 
MH1 is a DNA binding domain which carries the NLS (nuclear localization 
signal) and mediates specific DNA binding through the βH (β-hairpin) 
structure66. The additional exon (Ex3) of Smad2 interferes with its direct DNA 
binding67. MH2 is important for Smads oligomerization, and their specific 
interaction with TβRI or DNA binding partners. The SXS motif in MH2 at the C-
terminus of R-Smads is the target of activated TβRI. The L3 loop within MH2 is 
responsible for specific association between Smads and the L45 loop of TβRI 68,69. 
The linker area between MH1 and MH2 domains is unstructured and divergent. 
It is rich in serines and prolines that are targeted by diverse kinases, which 
promotes its interaction with various modulatory proteins, and thus facilitates 
cross-talk of TGFβ signaling with other signaling cascades. For example, the 
PPXY motif within the linker region is responsible for interactions with WW 
domain proteins (e.g. Smurfs, TAZ/YAP) for suppressing TGFβ signaling70,71. In 
Smad4, a SAD (Smad4 activation domain) exists instead of the PPXY motif, 
which determines the transcriptional activation of the Smads complex72. In I-
Smads (Figure 1.2.5 C), the MH2 domain is conserved, which enables them to 
interact with the type I receptors, but the MH1 domain is absent.  
Besides phosphorylation, activity of Smads is subjected to post-translational 
modifications. R-Smads are negatively regulated by ubiquitination for 
proteasomal degradation73, and are positively influenced by acetylation74,75. 
Smad4 could be mono- or ploy-ubiquitinated to promote Smads oligomerization 
or Smad4 degradation, respectively76. Smad4 was also found to be modified by 
SUMO-177. Moreover, I-Smads have been shown to be subject to acetylation, 
ubiquitination and methylation78,79. 
 
 
In addition to the canonical TGFβ signaling through intracellular Smads 
pathway, diverse cellular signaling transmitted through other mediators also 
occur upon TGFβ stimulation, which complements the Smad dependent actions. 
Examples of the non-Smad signaling are MAPK (mitogen-activated protein 
kinase) pathways, small GTPases, and translocation of the cleaved TβRI-ICD 
(intracellular domain of TβRI) (Figure 1.2.6). 
Recruitment of tyrosine kinases is related to TGFβ mediated MAPK signaling 
activation. On the one hand, TβRI has been found to be tyrosine phosphorylated 
upon TGFβ stimulation, the activated TβRI recruits and directly phosphorylates 
tyrosine and serine of ShcA proteins, which then recruit Grb2 and SOS to initiate 
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the Ras-Raf-MEK-Erk MAPK signaling cascade80. This leads to regulation of cell 
proliferation or cell migration. On the other hand, TβRII has been found to be 
phosphorylated on Tyr284 by Src. This is facilitated by TGFβ induced αvβ3 
integrin upregulation, which enables β3 integrin to physically interact with 
TβRII81,82. The phosphorylated Tyr284 then coordinates the selectively docking of 
the SH2 domains of Grb2 (growth factor receptor binding protein 2) and Shc (Src 
homology 2 domain containing) to TβRII, thereby couples TGFβ to p38 MAPK 
signaling activation42. This Src-dependent TGFβ signaling is related to breast 
cancer progression81. Furthermore, activated TβRI in LRC could recruit the 
ubiquitin ligase TRAF6 (TNF (Tumor necrosis factor) receptor associated factor 6) 
and enhance the auto-ubiquitination of it. TRAF6 then activates the catalytic 
function of the TAK1 (TGFβ activated kinase 1) by Lys63-linked 
polyubiquitylation, which in turn results in activation of the p38/JNK (c-Jun N-
terminal kinase) MAPK cascades. This MAPK signaling activation regulates 
apoptosis and EMT83,84. 
TβRII could regulate small GTPases, which plays an important role in TGFβ 
induced EMT (epithelial-to-mesenchymal transition). Briefly, TβRII is shown to 
phosphorylate the polarity protein Par6 (Partitioning defective 6 homolog), 
which then recruits the E3 ligase Smurf1 to ubiquitinate the small GTPase RhoA 
for localized degradation. Because the RhoA controls the assembly of tight 
junctions, loss of RhoA promotes dissolution of tight junctions and EMT, which 
plays important roles in early development, wound healing and disease like 
cancer85-87. Although Smad-dependent TGFβ signaling is indispensable for 
complete TGFβ-induced EMT, various studies demonstrate the importance of 
this non-Smad signaling in metastasis88. 
 
Figure 1.2.6  Examples of non-canonical TGFβ signaling. TGFβ receptors 
can signal independently of the Smads, to induce context dependent responses through 
activating various signaling pathways such as MAPK signaling, small GTPases, or direct 
transcriptional regulation by the cleaved TβRI-ICD. Different pathways are 
distinguished by different colors of arrows.  
 
  
β 13 
TGFβ could also induce cleavage of TβRI at Gly120 by TACE (TNF-alpha 
converting enzyme). The cleavage liberates the ICD of TβRI, and it is promoted 
via TRAF6 mediated polyubiquitination on TβRI89. The released TβRI-ICD 
translocates into nucleus and associates with p300 to transcriptionally regulate 
target genes involved in tumor invasiveness, such as MMP2 and Snail. 
 
 β
Consistent with many other cell surface receptors, TGFβ receptors undergo 
constitutive endocytosis and recycling, independent of ligand stimulation90. 
Therefore, aside from the presence of TGFβ receptors on the cell surface, there 
exists an intracellular pool of TGFβ receptors. There are two distinct ways of 
receptor internalization, clathrin-dependent and caveolin-dependent endocytosis, 
which have been regarded to positively facilitate and negatively regulate TGFβ 
signaling (Figure 1.2.7). 
The clathrin-dependent endocytosis on the one hand negatively regulates 
signaling transduction by decreasing the potent receptors on the cell surface and 
mediating receptor degradation; but on the other hand, it increases the proximity 
between the activated receptors and their downstream substrates or other 
signaling regulators in the cytoplasm, thereby enhancing TGFβ signaling. The 
clathrin-dependent internalization occurs through formation of clathrin-coated 
vesicles, which is dependent on the interaction between the intracellular domain 
of the receptors and the N-terminal trunk domain of the β2 adaptin subunit of 
AP2 (clathrin-associated adaptor protein complex) 91. Once LRC is internalized, 
TGFβ signaling is promoted by several positive regulators localized in the EEA1 
positive early endosomes, which are important signaling centers for signaling 
transduction. SARA (Smad anchor for receptor activation), Hrs/Hgs (hepatocyte 
growth factor-regulated tyrosine kinase substrate) and endofin are three typical 
positive regulators that reside in early endosome through their FYVE (Fab1, 
YOTB/ZK632.12, Vac1 and EEA1) domain92,93. SARA promotes R-Smads 
phosphorylation by functioning as a scaffold protein and facilitating the 
presentation of the R-Smads94. Hrs functions by binding to Smad2 and 
cooperating with SARA95. Endofin facilitates TGFβ signaling by interacting with 
Smad496. Besides, SARA also cooperates with the tumor suppressor protein cPML 
(cytoplasmic promeylocytic leukemia) and the adaptor protein DAB2 (disabled-2) 
for linking the receptors to Smads and stabilizing the complex, thus facilitating 
TGFβ signaling97,98. Due to the importance of the early endosomes for TGFβ 
signaling, the small GTPase Rab5, which regulates the early endosome dynamics, 
plays a crucial role in modulating TGFβ signaling 99,100. 
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A portion of the internalized TGFβ receptors will recycle back to the plasma 
membrane (PM), probably in the absence of ligand101. Recycling of the 
internalized receptors is dependent on Rab11, which marks the perinuclear 
recycling endosomes102,103. Besides, various regulators exist in controlling the 
recycling processes, such as CIN85 and DAB2/ Vps26 (retromer vacuolar protein 
sorting protein 26) for promoting TβRI and TβRII recycling, respectively104-106. 
 
Figure 1.2.7  Membrane trafficking of TGFβ receptors. TGFβ receptors 
undergo constitutive internalization and intracellular sorting through two distinct 
pathways: clathrin-dependent and caveolin-dependent pathways, to enhance and turn 
off signaling, respectively. In the clathrin-dependent pathway (blue), receptors are 
internalized via clathrin-coated pits. SARA, Hrs, Endofin, cPML and DAB2 cooperate to 
promote Smads signaling in the EEA1-rich early endosome. From there, a portion of the 
receptors can recycle back to the cell surface via the Rab11-positive recycling endosome; 
others are sorted to the Rab7-labeled late endosome, and then either enter the recycling 
procedure or continue to the lysosome to be degraded. In the caveolin-dependent 
pathway (red), receptors are internalized via caveolin-positive lipid rafts and enter the 
caveolin-positive endosome, then eventually reach the lysosome where the final protein 
degradation takes place. The caveolin-1 associates with TβRI and facilitates its 
interaction with Smad7, which carries ubiquitin ligase (e.g., Smurfs) and deubiquitylase 
(e.g., DUBs) to regulate the ubiquitination of the receptors as well as Smad7 itself. The 
distribution of TGFβ receptors on the plasma membrane is regulated by IL-6, ADAM12 
and heparin sulfate, hyaluronan-CD44 for shifting the receptors to the clathrin pits and 
lipid raft, respectively. This figure is adapted, modified from Heldin et al. (2016)26. 
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Caveolin-dependent endocytosis occurs through cholesterol-rich lipid 
rafts/caveolin-coated vesicles and acts to turn off the TGFβ signaling by 
promoting receptors degradation. Through this pathway, caveolin-1 associates 
with TβRI and facilitates its degradation in proteasomes or lysosomes through 
interaction with Smad7/Smurf complex 107,108. Besides the negative effects on 
TGFβ signaling, lipid rafts participate in several non-canonical TGFβ signaling 
pathways. For instance, caveolin-1 promotes TGFβ induced upregulation of type 
I procollagen via PI3K/Akt/mTOR signaling pathway109; cholesterol-rich lipid 
rafts mediate TGFβ induced MAPK activation110; eNOS (endothelial nitric oxide 
synthase) activation in lipid rafts is facilitated by its association with TGFβ 
receptors, which is inhibited by TGFβ stimulation111. Moreover, caveolin-1 
interacts with ALK1 and facilitates its signaling through Smad1/5112. 
TGFβ signaling is elaborately regulated by the balance between the two 
branches of internalization (i.e., clathrin and caveolin dependent endocytosis). IL-
6 (Interleukin-6) and AMAM12 (a disintegrin and metalloproteinase 12) could 
enhance the signaling through promoting trafficking of the receptors to the non-
raft pools113,114. While heparin sulfate and CD44 facilitate partition of the receptors 
to the lipid-rafts, resulting in attenuation of the signaling93. In addition, the 
regulation of N-glycan processing on the receptors also influences the TGFβ 
signaling through balancing their surface retention with internalization38. 
Interestingly, the rates of internalization and recycling are not affected by ligand 
binding102, while a decrease in ligand binding was shown upon ligand induced 
receptors oligomerization115. 
 
 β
As mentioned above, the function of TGFβ is versatile and even seemingly 
paradoxical: it can regulate different genes in different tissues; it can help ES cells 
maintain pluripotency, but also promote differentiation; it suppresses tumor 
progression in pre-malignant cells, but enhances metastasis in carcinoma cells. 
The contrast between the multi-functionality of TGFβ signaling and the simple 
central engine of the Smad signaling suggests that the cellular context rather than 
the cytokine itself dictates the specific responses12. Here, we list several examples 
of context-dependent specific TGFβ signaling. 
Cell-type-specific master transcription factors recruits TGFβ induced R-Smads 
to specific sites in the genome for orchestrating cell-type-specific regulation by 
TGFβ. For instance, Smad3 is recruited by Oct4 in ES (embryonic stem) cells for 
maintaining hES cell identity, by MYOD1 (myoblast determination protein 1) in 
mesenchymal progenitors for myogenic process, and by PU.1 in pro-B cells for 
regulation of cell differentiation fate116.  
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Besides, TGFβ is also a master of T cell trades, therefore a crucial player in 
immune or inflammatory functions by regulating T cell development, 
homeostasis, tolerance and differentiation, depending on specific cell types as 
well as environmental cues117. 
In hepatic and breast epithelial cells, or during palate fusion, heart 
development and renal fibrosis, with WNT providing the proper context, TGFβ 
could trigger EMT via two complementary pathways: first, a pathway of TβRI-
Smads-Snail/TWIST1 (TWIST-related protein 1) to repress the expression of a key 
epithelial cell junction gene, CDH1; second, a pathway of TβRII-Par6-Smurf-
RhoA to dissolve tight junctions12,88,118. 
In epithelial cells, neural and hematopoietic cells, the anti-proliferation effect 
of TGFβ is mainly mediated by activating the CDK (cyclin-dependent kinase) 
inhibitors and repressing the Myc. Specifically, in skin keratinocytes, the TGFβ-
induced Smads complex cooperates with FOXO (Forkhead box O) factors, ETS1 
(E26 transformation-specific proto-Oncogene 1) and AP2 to promote 
transcription of CDKN1A and CDNK2B. At the same time, the activated Smads 
complex interacts with E2Fs to inhibit Myc expression12. 
In premalignant cells where an oncogenic driver mutation appears, TGFβ 
triggers apoptosis and thus suppresses tumor progression. However, these cells 
tend to eliminate the tumor suppressive effects of TGFβ by accumulating more 
driver mutations on upstream signaling transducers such as TGFβ receptors and 
Smads (mainly happens in pancreatic and gastrointestinal carcinomas), or 
downstream effectors such as CDK4 inhibitor p15-INK4b (frequently happens in 
breast carcinomas, melanomas and gliomas). As a result, tumor cells withstand 
and even create a TGFβ-rich microenvironment which is profitable for tumor 
progression and metastasis12. 
 
 β
The principal components, the related regulators, as well as numerous target 
genes of TGFβ signaling were identified decades ago. Crystal structures of these 
components were gradually resolved28,47,119-128, and disease-causing mutations 
were also discovered to provide implications for medical applications129. With the 
development of the systems biology, mathematical models have been developed 
to aid the comprehension of signal processing dynamics in the TGFβ signaling 
pathway130-136. However, due to the vagueness or the poor resolution of the 
current available biological experimental methods, it is still very far away from 
quantitatively understanding the wring of the TGFβ regulated molecular 
network in different context, as well as the dynamics of TGFβ signaling under 
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various perturbations. Ergo, precise control of TGFβ signaling is urgently 
demanded for practical applications, especially at the single cell level. 
Several efforts have been made to manipulate the canonical TGFβ signaling.  
At the level of controlling TGFβ receptors, synthetic surfaces presenting ligand 
peptides to TGFβ receptors have been generated to preorganize these receptors 
and potentiate local TGFβ signaling, sensitizing bound cells to subpicomolar 
concentrations of TGFβ, therefore precise spatial control could be achieved137. 
Chimeric receptors that could be activated by chemically-induced dimerization 
have also been constructed for isolating and interrogating the characteristics of 
specific receptors138-140. Small molecular inhibitors have been screened or 
developed to inhibit the kinase activity of the TGFβ receptors141-143. At the level of 
controlling TGFβ ligands, antisense oligonucleotides/RNAs and antibodies have 
been designed to modulate the activity of the TGFβ ligands144-147. 
All of these strategies depend on the preparation and administering of small 
chemicals or even antibodies to stimulate the cells. The recent development of the 
field of optogenetics provides us with an alternative option to activate cells: 
shining light on cells. Light stimulation is superior to the traditional ligand 
stimulation on several aspects (Table 1.2-1). Firstly, light is much more 
convenient to manipulate. With light sources (of certain wavelengths) and a 
coupled electric controller, any patterns of stimulation could be realized by 
coding in the software. Secondly, with light, spatiotemporal control could be 
easily achieved at the subcellular resolution, just as structures of subcellular 
objects could be accessed under a modern microscope. In addition, the procedure 
of medium change (which is necessary for ligand stimulation) might play as a 
stimulus, and thus might interfere with the results. Light stimulation avoids this 
interference by avoiding the necessity of medium change. 
 
Table 1.2-1 Comparison of light and ligand for perturbing cell signaling 
 Light Ligand 
Manipulation Convenient Inconvenient 
Spatiotemporal control Precise Poor 
Need Medium Change No Yes 
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Optogenetics is a recently developed field of study, which involves using light 
to control the activities of proteins or cellular functions in living cells by 
introducing light-sensitive proteins. At the beginning, optogenetic tools were 
mainly developed on light-sensitive ion channels for modulating membrane 
voltage potential, which has transformed the neurosciences. Later on, another set 
of optogenetic tools have emerged and quickly been developed to allow control 
of molecular interactions and signaling cascades. Due to the convenience and 
precision of manipulating light stimulation, optogenetics is a powerful tool to 
achieve high spatiotemporal resolution, which is not only beneficial for scientific 
research, but also a potent approach for therapeutic application. 
 
 
Neuronal communication is based on the ‘switch’ between the activation of 
transient electrical signals (spiking) by membrane depolarization, and the 
inhibition of these signals by membrane hyperpolarization. To study the 
functional relationships among the various neurons, and their individual 
contribution to the network functions or certain behaviors, it is necessary to 
precisely target and control the electrical activities in specific neurons.  
Nowadays, a toolbox of light-activated neuronal switches is available for 
precisely operating the currents in neurons, by converting light into electricity 
(Figure 1.3.1). They were borrowed and developed from the natural world, in 
which photo-sensory or photosynthetic molecules prevail throughout the 
kingdom of life. By exogenously expressing these light-sensitive tools in certain 
neurons, we could turn them on or off by shining light on them. Therefore, light 
could be converted to electricity, and thus be used as an on-off switch to control 
the membrane potential in these cells.  
ChR2 (Channelrhodopsin-2) is among the first ones in this toolbox. In response 
to blue light activation, it acts as a nonselective cation channel and triggers a 
spike to depolarize the neuron148. Another protein, VChR1 (Volvox 
channelrhodopsin-1) was also identified to induce spiking, in response to red-
shifted light149. Besides activating the neuronal signaling, tools for 
hyperpolarizing neurons (thus inhibiting the signaling) were also identified and 
developed. For example, NpHR (halorhodopsin) works as a chloride pump 
under yellow light irradiation to block signaling by hyperpolarizing the neuron150; 
Arch (archaerhodopsin-3)151, fungal opsins Mac152, GtR3 (rhodopsin-3)153, and BR 
(bacteriorhodopsin)154 all work as light-sensitive proton pumps, which could be 
applied to inhibit spikes through hyperpolarizing neurons. 
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The toolbox is also expanded by reengineering the existing naturally occurring 
genes. For example, ChETA155 and SFO156 mutants derived from  ChR2, are faster 
and slower versions of ChR2, respectively; eNpHR (enhanced halorhodopsin) 
mutants from NpHR, show improved membrane targeting property157; and  eBR 
is a mutant of BR with enhanced performance in cultured neurons 153. 
 
 
Figure 1.3.1  Optogenetic tool box for modulating membrane voltage 
potential158.  ChR2 and its derivatives could activate transient electrical signals by 
membrane depolarization; NpHR (woking as a chloride pump), Arch (functioning as a 
proton pump) and their derivatives could inhibit signals through different ways. This 
figure is adapted, modified from Pastrana (2011)158. 
  
Since its advent, optogenetics has revolutionized the landscape of 
neuroscience by providing a set of tools enabling us to efficiently probe the 
specific neural circuit components. It has been successfully employed to promote 
our understanding of not only the neural circuits mediating normal behavior, but 
also its aberration underlying the dysfunctional behavior or psychiatric diseases, 
including addiction, mood disorders, obsessive compulsive disorder, and 
Parkinson’s disease, among others159. 
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Recent years, the field of optogenetics has moved beyond the toolbox of light-
gated ion channels, another toolbox is also quickly developed, for modulating 
cell signaling. In this toolbox, photosensitive proteins undergo reversible 
conformational changes in response to specific light wavelength, which alters 
their binding affinities, resulting in diverse light-induced activities. Therefore, 
when fusing a signaling domain to the light-sensitive protein or its partner, it is 
easy to achieve inducible protein association, gene regulation, clustering-based 
activation/inhibition, or conformational change160-163 (Figure 1.3.2). 
 
Figure 1.3.2  Strategies for controlling cell signaling optogenetically. 
The optogenetic tools could be applied to modulate cell signaling through various 
approaches. When fusing the signaling domain to a light-sensitive protein or its partner, 
we could achieve inducible protein association by heterodimerization; gene expression 
by recruiting transcription activators; clustering-based activation or inhibition through 
regulating the densities of the signaling domains or being sequestered, respectively; and 
conformational change to conceal or relieve a signaling domain. Waved arrows indicate 
the response to light stimulation. Straight arrows in the opposite direction indicate 
reversion in dark or in response to an alternative light wavelength. This figure is 
adapted, modified from Tischer et al. (2014)164.  
 
Currently available photosensitive modules in this toolbox spread throughout 
the spectrum between UV (Ultraviolet) and infrared (infra-red) wavelengths 
(Figure 1.3.3). They vary not only in absorption spectrum, but also in size and 
turn-on/turn-off kinetics (Table 1.3-1). Some of them need us to supply the cells 
with exogenous chromophores (e.g. PCB), but others employ chromophores that 
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are endogenous in mammalian cells (e.g. flavin). It is of prime importance to 
compare these properties and then select proper optogenetic modules for 
developing the light-controllable cell signaling system. The best appropriate 
module is also dependent on the properties of the cell signaling to be controlled, 
as well as the compatibility of the fluorescent proteins. By taking the advantage 
of the diversity of optogenetic modules, multi-chromatic control of cellular 
activity is also possible for achieving more layers of manipulation165. 
 
Figure 1.3.3  A diversity of photosensitive modules.  The localization of 
each module on the spectrum indicates the color of its activation light.  
 
 
Optogenetic modules for manipulating cellular signaling are derived from 
photosensitive modules of organisms throughout the kingdom of life, including 
bacteria, fungi, plants and mammals. A variety of biological phenomena are 
induced by light stimulation, including visual perception, flowering, 
phototropism and phototaxis. Upon specific light absorption, the chromophore of 
the photo-sensory module is excited and transformed by photochemical reactions, 
which induces the amino acid backbone of the photosensitive protein to undergo 
rearrangement. This conformational alternation then activates the photosensitive 
module through undocking or affecting their protein-protein interactions 166. In 
addition to the natural occurring photo-sensors, the toolbox for modulating cell 
signaling is also expanded by artificial ones which are developed through 
mutations. 
Phytochromes 
Phytochromes are a set of photoreceptors at the far-red end of the spectrum in 
the toolbox. Bacterial BphP1 (bathy phytochrome1) is activated by infrared light 
and binds to its natural partner PpsR2; PhyB (phytochrome B) from Arabidopsis 
thaliana is activated by red light irradiation and binds to its cofactor PIF3 or PIF6 
(phytochrome interacting factor); while Cph1 (cyanobacterial phytochrome 1) 
undergoes homodimerization in response to red light stimulation. Notably, all 
these activation processes could be efficiently reversed by another wavelength. 
This dual optical controllability could benefit higher level of quantitative 
perturbation and regulation of the biological activity. PhyB-PIF3/PIF6 
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heterodimerization has been applied to study Rho GTPase and MAPK signaling 
pathways, and also has been used to control the nuclear shuttling of proteins. In 
addition, bilin molecules are needed as the chromophores of the phytochromes: 
PΦB (phytochromobilin), PCB (phytococyanobilin) and BV (biliverdin IXα) are 
for plant, cyanobacterial and bacterial/fungal phytochromes, respectively. 
Among them, BV is endogenously expressed in all cells and thus not necessary to 
be supplied externally.  
Fluorescent proteins 
Fluorescent proteins could also be modified and developed to be optogenetic 
tools. Dronpa is a monomer GFP (green fluorescent protein) that undergoes 
reversible transitions between dark and fluorescent states by cyan and violet light 
stimulation, respectively. The substitution of K145N generates a light-switchable 
module, Dronpa145N, which forms tetramers at the micro-molar concentration in 
the dark, or upon violet light irradiation, and forms monomerizes upon blue light 
stimulation167. The light-switchable tetramerization/monomerization of 
Dronpa145N has mainly been applied to uncage and thus activate proteins such 
as the Cdc42 GEF (guanine nucleotide exchange factor) ITSN (intersectin), or the 
NS3-4A protease167. 
Cryptochromes 
Cryptochromes are probably the most widely used photoreceptors across the 
evolutionary lineages of bacteria, plants and animals168. They respond to blue 
light irradiation, and implement diverse crucial biological functions such as 
magneto-reception, plant development and circadian rhythms169. The 
chromophore incorporated by cryptochromes is a single molecule of FAD (flavin 
adenine dinucleotide), which non-covalently binds to the PHR (photolyase 
homology region) domain of the cryptochromes. Upon blue light irradiation, the 
FAD is reduced, which induces conformational changes of the PHR domain into 
the biological active form. The activated cryptochromes could recover to the 
original state when blue light is off. Among the cryptochromes, CRY2 
(cryptochrome 2) of Arabidopsis thaliana is widely adopted to optogenetically 
control protein homodimerization or heterodimerization. The activated CRY2 
forms homooligomers, or forms heterodimers with CIB1 (cryptochromes-
interacting basic helix-loop-helix 1). The photoactivation occurs in microseconds 
upon blue light irradiation, and the activated CRY2 resets to its dark state within 
minutes, followed by the complex dissociation170. A CRY2 mutant, CRY2olig with 
an E490G mutation in the PHR domain, shows enhanced oligomerization ability, 
and could be used as an efficient optogenetic tool for clustering-based activation 
or sequestration171. The photocycle kinetics of the CRY2-CIB1 dimerization 
module have also been further optimized, through perturbing the α13-α14 turn 
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motif of CRY2172. Currently, a truncated version of the CRY2-CIB1 module, 
CRY2PHR (amino acids 1-498)-CIBN (amino acids 1-170) is more commonly used 
due to the smaller size and low basal activity173. The oligomerization ability of 
CRY2 has been applied to proteins that require oligomerization or dimerization 
for activation, such as LRP6, FGFR, hROS1, FGFR, Raf and Trk (tropomyosin-
related kinase) receptors166. The heterodimerization of the CRY2-CIB1 module has 
been applied to study apoptosis, small GTPases, kinesin motor KIF5A, dynein 
adaptor protein BICDN, MAPK or PI3K/AKT signaling pathways174. 
LOV domains 
LOV (light-oxygen-voltage) sensing domains are another category of blue light 
sensitive units, which incorporate flavin chromophores, including FMN (flavin 
mononucleotide) and FAD. The LOV domain family exists in prokaryotes, fungi 
and plants, and all of the LOV domains contain a conserved PAS (Per-Arnt-Sim) 
core flanked by helical elements. Blue light could activate the flavin 
chromophores, which then form an adduct with a cysteine residue in the PAS 
core, resulting in conformational changes of the LOV domain. The adduct is 
gradually hydrolyzed in the dark, and the LOV domain reverts to its initial state.  
Three kinds of LOV domains are commonly used in optogenetics: FKF1 
(flacin-binding, Kelch repeat, F-box protein), AsLOV2 (Avena sativa LOV domain 
2) and VVD (vivid). Upon photoexcitation, FKF1 undergoes dimerization with its 
binding partner GI (GIGANTEA) within minutes, and the association is stable for 
hours after turning off the light. The FKF1-GI system has been applied for RAC1 
activation through plasma membrane (PM) recruitment of a constitutively active 
RAC1 mutant lacking the CAAX motif175. AsLOV2 is from the phototropin 1 of 
Avena sativa, its PAS core is flanked by two α-helix, A’α and Jα which unfold and 
detach from the core within seconds upon light-induced conformational change 
of the core176. This light induced dissociation of Jα from the LOV2 core makes it 
an efficient optogenetic uncaging approach, and has been applied for uncaging of 
Caspase7, Rac1, Cdc42, mDia1, and uncaging of PKI (protein kinase inhibitory) 
peptides for inhibition of PKA (protein kinase A). VVD is the smallest 
homodimerization tool in the optogenetic toolkit, which reversibly forms 
homodimer via its Ncap (N-terminal Cap) in response to blue light.  
Variants of these LOV domains have been engineered to expand the 
optogenetic toolbox. A variety of AsLOV2 mutants improve the dynamic range 
of the LOV-Jα system. AsLOV2 based LINuS (light-inducible nuclear localization 
signal), LEXY (light-inducible nuclear export system) and LANS (light-activated 
nuclear shuttle) systems have been developed to control nuclear shuttling of 
proteins 177-179. Two other AsLOV2 based systems, iLID (improved light inducible 
dimer) and TULIPs (tunable, light-controlled interacting protein tags), provide 
photoinducible heterodimerization tools, which have been applied for recruiting 
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specific proteins to target sites in various studies174,180-182. Magnets pair of pMag-
nMag is derived from VVD for strict heterodimerization, through exchanging the 
neutral amino acids at the homodimer interface of wildtype VVD with positively 
or negatively charged ones 183. 
UV receptors 
UVR8 (UV-B resistance 8) as an optogenetic tool resides at the ultra-violet end 
of the spectrum. The default state of UVR8 in the dark is in the form of 
homodimer, mediated by salt bridges at the interface. No incorporated 
chromophore is needed for UVR8 activation. Instead, the intrinsic tryptophan 
residues clusters around the homodimer interface could be excited by UV-B and 
destabilize the salt bridges, resulting in rapid dissociation of the homodimer into 
monomers, which can interact with its binding partners such as COP1 
(constitutive photomorphogenesis protein 1). Compared with the fast 
dissociation upon light irradiation, interaction of UVR8-COP1 is stable for hours 
in the dark166. Therefore, this optogenetic system has mainly been applied for 
recruiting transcription activation domain to induce gene expression, or 
triggering protein secretion166. 
BLUF domains 
BLUF (blue light utilizing FAD) domains are mostly found in proteins of 
bacteria and algae. They employ FAD as chromophore and undergo 
conformational changes triggered by blue light activated FAD reduction. In 
contrast to other optogenetic systems which affect cell signaling through 
modulating protein interactions, BLUF domain-based optogenetic systems have a 
predefined function of photo-inducible adenylyl cyclase activity, regulating 
cAMP production. euPAC and bPAC, derived from Euglena gracilis and Beggiatoa 
respectively, are two commonly used BLUF domains in optogenetics166. A novel 
light-inducible guanylyl cyclase is engineered by replacing the amino acid 
residues at the substrate binding pocket of bPAC, resulting in its substrate 
specificity for guanosine instead of adenosine184. 
The optogenetic toolboxes are continuously expanding, evolving and being 
optimized. Novel photo-sensitive proteins are being discovered and added to the 
toolboxes. The currently available tools are being optimized on every aspect, 
including the light-induced activation/recovery kinetics, the affinities, and the 
wavelength for photo-switching. Because most of these tools are adapted from 
photo-sensors from other kingdoms such as plants or bacteria, they are 
orthogonal to the endogenous cell signaling cascades in mammalian cells, which 
could improve the predictability of the signaling. However, codon optimization 
for mammalian expression is necessary to be done to improve their expression 
efficiency, as well as their proper functionality in the target cells. 
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Besides its non-invasive way to act on cells, light has great advantages as a 
stimulus, because it could be manipulated conveniently, in terms of intensity, 
specific space and time. Therefore, optogenetic approaches benefit biological 
analysis or signaling manipulation through isolating distinct sub-circuits, 
quantitatively analyzing responses to specific stimulations, controlling cellular 
signaling in space, and controlling cellular signaling in time (Figure 1.3.4). 
 
 
 
Figure 1.3.4  Schematics depicting the advantages of optogenetic 
control.   (A) Optogenetics enable isolating specific sub-circuits with precise and 
defined inputs control. (B) Optogenetics facilitates analyzing the input-output behavior 
quantitatively. (C) Optogenetic regulation of signaling in space, for both multicellular 
signaling (upper panel) and subcellular signaling (lower panel). (D) Optogenetic 
regulation of signaling in time, specific illumination pattern could elicit specific response. 
Wavy arrows denote light input.  
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Isolation of distinct sub-circuits 
Cellular signaling networks often display a complex, interconnected 
architecture with cross-talks and feedback regulations, which makes it 
challenging to disentangle specific sub-circuits by the traditional chemical 
perturbation experiments. Chemicals, especially ligands, could induce various 
branches of a signaling cascade, and other side-effects such as off-target are often 
unavoidable. This often complicates the biological analysis by affecting the 
topology of the signaling network. In contrast, in optogenetic studies or 
applications, only the proteins containing the light-sensitive modules would 
response to perturbations of specific optical stimulation. Consequently, through 
dissecting a signaling pathway and uncoupling specific signaling arms from it, 
optogenetic modules provide efficient tools to study the specific sub-circuits 
within the full complex signaling network. 
Growth factors activate both PI3K/Akt and Ras/Erk signaling with possible 
crosstalks between them, Toettcher et al. built an optogenetic system to 
selectively activate the Ras/Erk branch and follow the information flow in it204. In 
another example, the PI3K and Akt signaling was selectively activated in time 
and space to reveal their distinct roles in adipocyte insulin action205. More and 
more other studies apply optogenetic controls to access distinct nodes in the 
physiological signaling network. 
Quantitative control and analysis of signaling responses 
The quantitative control of light input makes optogenetics an efficient way to 
interrogate how upstream signaling is quantitatively transmitted to the specific 
downstream responses. Optogenetics facilitates quantitative analysis of cell 
signaling through precisely controlling optical stimulations, then quantitatively 
measuring cellular responses to specific stimulations, and finally determining the 
logic of the signaling information flow. For example, by applying various 
illumination patters to a photo-activable Akt system, and recording the 
corresponding time course data of Akt activation, Katsura et al. developed a 
computational model, which enables quantitatively control the Akt activity206. 
Besides the direct assignment of light input pattern, it is also possible to 
deploy a closed-loop in-silico feedback module to maintain a certain response 
level. In this optogenetic strategy, live-cell response readout is monitored in real 
time, and is compared with a target response level. A proper light input that 
would minimize the deviation between them is then calculated in silico and 
applied to the cells207,208. This could robustly clamp the desired response levels, 
despite the inevitable biological fluctuations and modeling inaccuracies. 
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In addition, properties of biological systems such as gradient sensing, 
frequency response or fold change detection could be studied more conveniently 
by optogenetic approaches209-211. 
Control of signaling in space 
Spatial regulation of cell signaling is important at levels of both organismal 
biology and cellular processes coordination. Therefore, optogenetics provides 
excellent tools for manipulating signaling in space, to understand spatial 
regulation of multicellular signaling, as well as subcellular signaling. 
Cell-to-cell communication is crucial for biological processes such as 
development and signal gradient interpretation. In contrast to chemical treatment, 
which is hard to target specific cells in a population due to the inherent diffusion 
property, light stimulation could spatially restrict activation to certain light-
sensitive cells. For example, propagation of signaling between adjacent cells is 
found in STAT3 signaling and ERK activity pulses 204,212. Lateral inhibition is a 
rational way to sharpen signal interpretation in the eyes and other multicellular 
contexts 164,213. These are only possible to be investigated by precisely controlling 
the inputs in space. 
At the subcellular level, optogenetic systems enable studies on coordinated 
cellular processes, such as cell polarization or cellular movement in vivo. By using 
AsLOV2 to control Rac1, Wu et al. demonstrated conditional lamellipodia 
formation only at illuminated subcellular sites162. As another example, in one 
study on individual neutrophil migration in zebrafish, Rac was photo-activated 
locally at the leading edge, resulting in protrusion but not polarization. This 
demonstrates a two-tiered PI3K-mediated cell motility regulation paradigm214. In 
a third study, optical control of MAPK signaling by locally recruiting Cdc24 
resulted in light-directed polarized growth181. Combining mathematical models 
that incorporate spatial information of each signaling node, cellular signaling 
activity could be better characterized215.  
Control of signaling in time 
Biological information is not only encoded in the current level of signaling, but 
also encoded in the dynamics of signaling over time (Figure 4.3.2), which largely 
extends the complexity of biological information flow216. For example, transient 
or sustained Erk signaling induced by EGF (Epidermal growth factor) or NGF 
(Nerve growth factor), results in cell proliferation or differentiation, respectively; 
oscillated or sustained level of nuclear NF-κB induced by TNFα or LPS, triggers 
inflammatory response genes or adaptive immune response genes, respectively; 
repeated small pulses or a single larger pulse of p53 induced by γ-radiation or 
UV radiation, are associated with cell cycle arrest or apoptosis, respectively217. 
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Therefore, manipulating and decoding the timing of signaling are of crucial 
importance for investigating and controlling the specific cellular functions. 
Optogenetics approaches have shown their power in manipulation of 
temporal signaling pattern. By applying the PhyB-PIF module to recruit RasGEF 
to the plasma membrane, researchers could activate Ras by illuminating specific 
cells in various patterns. This work elucidates how the Ras/Erk module can 
specify distinct physiological outcomes204. In a recent study, the optogenetic 
platform was applied to isolate Raf/Erk or Akt signaling pathway and implement 
precise time-variant input, demonstrating the precise timing of Raf/Erk and Akt 
activation is crucial in protecting the PC12 cells against oxidative injury218. 
Temporal effects of Raf/Mek/Erk or Akt on other cellular functions or in other cell 
types have also been revealed206,219. In another study, optogenetic manipulation of 
the duration of Nodal signaling showed that extended Nodal signaling within 
the organizer suppresses endoderm differentiation, while it promotes prechordal 
plate specification. This suggests the temporal pattern of Nodal signaling 
determines cell fate specification during gastrulation220.  
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Due to the various advantages of using optogenetic approaches to interrogate 
signaling pathways, we attempted to apply optogenetic tools to manipulate 
TGFβ signaling. First, we questioned how likely it would be successful to build a 
synthetic TGFβ system. By referring to the literature, we found that TGFβ 
signaling could be triggered by association between the two types of TGFβ 
receptors. Since optogenetic modules could be applied to control protein 
association, it is feasible to build a light-controllable TGFβ signaling system. 
Second, to decide the best-fit photosensitive module for manipulating TGFβ 
signaling, we compared different properties of the diverse modules in the 
optogenetic toolkit. PHR-CIBN, which is a simplified version of a phytochromes 
module, turned out to be a promising one. Third, we tried to design a chimeric 
light-controllable TGFβ system (optoTGFβ) by considering the details, such as 
the subcellular localization of the chimeric proteins, and the fluorescent protein 
usage. The final design of the optoTGFβ system consists of a pair of optoTβRs 
(optoTβRI: Myr-cytoTβRI-CIBN; optoTβRII: cytoTβRII-CRY2PHR-tdTomato) and 
a TGFβ signaling readout (iRFP-Smad2). By molecular cloning and stable 
transfection, we established cell lines that stably expressing the optoTGFβ system, 
and confirmed the synthetic protein expression by western blotting experiments. 
 
 2 
 Development of the optoTGFβ System 
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The first step of TGFβ signaling following ligand binding is the recruitment of 
TβRI by TβRII. Therefore, the most intuitive way to control TGFβ signaling is 
through manipulating the association between the receptors. The first question 
would be: is it possible to trigger TGFβ signaling by simply bringing the 
receptors together?  
Referring to the literature, researchers have tried to construct chimeric TGFβ 
receptors by fusing the cytoplasmic region of the TGFβ  receptors to chemical-
binding proteins (e.g., EPOR)138 or other ligand-binding proteins (e.g., FKBP12 
and FRB)139, and successfully activated TGFβ signaling with the corresponding 
chemicals or ligand (Figure 2.1.1). These studies demonstrate that, neither the 
extracellular domains nor the transmembrane regions of the receptors is 
indispensable for TGFβ signaling activation, as long as the cytoplasmic region of 
TβRI could be taken closely enough to TβRII, by any means. Therefore, we 
concluded that it is feasible to activate TGFβ signaling by applying optogenetic 
tools, through the inducible protein association strategy (Figure 1.3.2). 
 
Figure 2.1.1  TGFβ signaling by other ligands or chemicals.  (A) EPO 
could induce TGFβ signaling by replacing the extracellular domains of the TGFβ 
receptors with the extracellular domain of the EPO receptor138. (B) TGFβ signaling could 
be activated by small chemicals when fusing the TGFβ receptors to the corresponding 
chemical binding proteins139. ‘cyto’ denotes the cytoplasmic region.  
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In the optogenetic toolbox, lots of photosensitive modules could be used to 
induce protein association. To choose the best one, we should inspect and 
compare the properties of different optogenetic modules. Firstly, the shorter the 
wavelength, the more toxic the light is to the living cells, thus it would be safer to 
use longer wavelength for activation/deactivation in experiments. Secondly, in 
order to control and monitor activities of each type of TGFβ receptor 
independently, it would be better to use the hetero-dimerization strategy, i.e., 
fuse the light-sensitive protein or its binding partner to TβRI or TβRII 
respectively. Thirdly, the speed of activation/deactivation should be considered. 
Fast turn-on/turn-off rates are more preferred. Fourthly, size and conformation of 
the optogenetic modules should also be taken in to account. Fifthly, regarding the 
chromophore usage, every coin has two sides: on the one hand, modules 
requiring exogenous chromophore (e.g. PCB) need to be supplied with 
chromophore for activation, which is not as convenient as those modules 
requiring endogenous chromophore (e.g. flavin). However, on the other hand, 
this also means that when handling the cells (e.g., during the cell culturing or 
FACS sorting), it is not necessary to avoid light of the corresponding wavelength, 
which might accidently activate the signaling.  
By considering these various aspects, we decided to start with the CRY2-CIB1 
module. This module has been successfully used to control the activity of 
receptors of another signaling pathway (Figure 2.2.1) 221, which also makes the 
CRY2-CIB1 module a promising tool to manipulate TGFβ signaling. As the PHR 
domain of CRY2 and the N-terminal region of CIB1 have the full function of 
light-inducible association, we would use this simplified version, PHR-CIBN in 
this study170. 
 
Figure 2.2.1 Schematic representation of wild-type (WT) FGFR1 (A) and 
optoFGFR1 (B).  (A) FGF ligand induces homodimerization of the FGFR1 receptors on 
the plasma membrane, followed by transphosphorylation and downstream signaling. (B) 
Dimerization and activation of the FGFR1 is induced by CRY2 clustering upon blue light 
stimulation. Myr, the myristoylation sequence.  
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Up to now, we have considered a pair of TGFβ receptors, and a photo-
inducible heterodimerization module (PHR-CIBN), to achieve the light-
controllable TGFβ signaling activation. To report the activation of the TGFβ 
signaling, we need readout. Since the nuclear translocation of Smad2 is a core 
step in TGFβ signaling, we decided to make use of this property. By tagging 
Smad2 with a fluorescent protein, the activity of Smad2 could be easily 
monitored under the microscopy. In addition, it would be better to follow the 
activity of the receptors by tagging them with fluorescent proteins as well. 
Furthermore, the localization of the chimeric receptors hasn’t been determined, 
i.e., is it necessary to attach the receptors on the plasma membrane (PM), or better 
to leave them in the cytosol? Therefore, we have a pool of spare parts (Figure 
2.3.1), from which there are various possible combinations to construct a light-
controllable TGFβ signaling system. 
 
Figure 2.3.1  The spare parts for constructing a light-controllable TGFβ 
signaling system.  PHR, the PHR (photolyase homology region) domain of CRY2; 
CIBN, the N-terminal region of CIB1; Myr, the myristoylation sequence for membrane 
targeting; FPs, fluorescent proteins. 
 
First of all, concerning the subcellular localization of the chimeric receptors, 
we decided to fix one of the receptors to the plasma membrane, leave the other 
one free in the cytosol, and tag the cytoplasmic one with a fluorescent protein. 
This design has two advantages: (1) it could separate the two receptors physically 
to avoid high basal activation, in the situation of no stimulation; (2) it would 
allow us to monitor the activities of the TGFβ receptors through tracking their 
localization and the association between the two TGFβ receptors. 
Second of all, the usage of fluorescent proteins (FPs) should be carefully 
considered. Although there are various available FPs spread through the 
spectrum, as the PHR-CIBN system could be activated by blue light (~480 nm), 
FPs around the yellow, green and blue light spectrum should be avoided. This is 
to make sure that the PHR-CIBN system would not be activated when observing 
and exciting the FPs under the microscopy. Thus it doesn’t leave us too many 
  
β 35 
options:  we could only choose FPs in the orange to far-red spectrum, and the 
selected FPs should be compatible, i.e., their excitation or emission wavelengths 
should not overlap. In the end, we chose tdTomato and iRFP682 considering that 
they are bright enough and compatible with each other (Table 2.3-1). 
 
Table 2.3-1  Properties of tdTomato and iRFP682 
FP 
Ex a) 
(nm) 
Em b) 
(nm) 
EC c) MB d) 
Matura-
tion e) 
Photo-
stability f) 
Oligomer-
ization 
Ref 
tdTomato 554 581 69,000 48,000 1h 64 dimer 222 
iRFP682 670 682 90,000 12,600 4.5h 490 dimer 223 
a) Excitation wavelength (nm). 
b) Emission wavelength (nm). 
c) Extinction coefficient, capacity for light absorption at the main peak ((M*cm)-1). 
d) Molecular brightness, product of molar extinction coefficient and quantum yield ((M*cm)-1).  
e) half-times (t 1/2) for combined folding and chromophore formation at 37 °C. 
f) Time for bleaching (t 1/2) from an initial emission rate of 1,000 photons/s down to 500 
photons/s (sec).  
 
Taking into account the above aspects, we tested different combinations of 
Myr, TGFβ receptors, PHR/CIBN and FPs. Some combinations didn’t respond to 
the blue light stimulation at all.  Some others did respond but the basal activity is 
very high (i.e., a high level of nuclear Smad2 was observed even without light 
stimulation). Finally, we selected one combination with correct response to light 
activation, and with low basal activity. 
In summary, we designed a light controllable TGFβ signaling system, the 
optoTGFβ system, by introducing the light-sensitive module, PHR-CIBN, which 
can interact with each other rapidly and reversibly upon blue light irradiation. 
TGFβ signaling can therefore be trigged ON and OFF at the single cell level by 
manipulating the illumination pattern. This system is composed of a pair of 
chimeric receptors which could initiate TGFβ signaling in response to blue light 
stimulation, and a TGFβ signaling reporter which facilitates monitoring the 
signaling activity. 
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Figure 2.4.1  The development of the optoTGFβ system. (A) Schematic 
representation of the optoTGFβ system. (B-D) The design of the optoTGFβ constructs. 
optoTβRI, the cytoplasmic region of TβRI was inserted between the myristoylation 
signal peptide (Myr) and CIBN (B). optoTβRII, the PHR domain of CRY2 was fused to 
the cytoplasmic region of TβRII, and tagged with tdTomato (C). Far-red fluorescent 
protein iRFP682 was tagged at the N-terminal of Smad2 (D). TM, transmembrane region. 
 
The final design of the optoTGFβ system is shown in Figure 2.4.1. Each protein 
of the light-sensitive module, PHR-CIBN, is fused to cytoplasmic regions of each 
of the TGFβ receptor pair, TβRII-TβRI, generating optoTβRII (cytoTβRII-
CRY2PHR-tdTomato) and optoTβRI (Myr-cytoTβRI-CIBN) (Figure 2.4.1 B-C), 
respectively. In addition, optoTβRI is attached to the plasma membrane, but 
optoTβRII is left floating around in the cytosol, and is tagged by an orange 
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fluorescent protein, tdTomato. This design could on the one hand, separate the 
chimeric receptors physically to avoid high level of basal TGFβ signaling activity, 
and on the other hand allow us to follow the association between the two 
chimeric receptors. Furthermore, Smad2 is tagged by a far-red fluorescent protein 
iRFP682, to report the activation of the TGFβ signaling (Figure 2.4.1 D). 
Theoretically, in the dark, both optoTβRII and the fluorescence labeled Smad2 
are in the cytoplasmic region of the cells. Upon blue light stimulation, the 
association between the PHR-CIBN pair will bring optoTβRII to optoTβRI, which 
localizes on the plasma membrane. This will result in the translocation of 
optoTβRII from the cytoplasm to the plasma membrane, which could be 
observed under the microscopy via monitoring its FP tag. The association 
between the chimeric receptors facilitates the phosphorylation and activation of 
optoTβRI by optoTβRII. This will in turn initiate the TGFβ signaling transduction, 
indicated by the nuclear translocation of the FP-tagged Smad2. The active Smad2 
then binds to target sites of the genome to regulate specific transcriptional 
activities. 
This light induced activation is reversible. Once the blue light is turned off, the 
active PHR will reset to its inactive form in minutes and leave CIBN, resulting in 
optoTβRII returning to the cytoplasm, which is followed by the recovery of 
Smad2. 
 
 β
After classical molecular cloning and stable transfection of the plasmid 
encoding the chimeric receptor pair, pLNCX2-optoTβRs, most of the stably 
transduced cells showed membrane localization of optoTβRII even without light 
stimulation (Figure 2.4.2 A). This might be due to the failure of separation at the 
P2A element of the constructed sequence. In the plasmid of pLNCX2-optoTβRs, a 
P2A element is inserted between the sequences of the optoTβRI and optoTβRII. 
Theoretically, optoTβRI and optoTβRII are transcribed to the same mRNA, which 
is translated before being cleaved at the P2A site into two individual proteins. 
However, failure of separation at the P2A element will lead to a consistent 
association between optoTβRI and optoTβRII, so that optoTβRII is always 
attached to the plasma membrane. Fortunately, there were a few colonies 
showing cytoplasmic localization of optoTβRII (Figure 2.4.2 B). When irradiated 
by a short pulse of blue light (488nm), optoTβRII in these cells translocated to the 
plasma membrane immediately (Figure 2.4.2 C). These cells, with the expected 
localizations of optoTβRII, were further transfected by the plasmid encoding the 
iRFP682-Smad2 protein. 
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Figure 2.4.2  Different optoTβRII localization in cells stably 
transfected with the plasmid pLNCX2-optoTβRs.  Scale bar: 25 μm. (A) Most cells 
transduced with pLNCX2-optoTβRs showed membrane localization of optoTβRII 
(shown as yellow) even without light stimulation. (B-C) A single colony showed 
cytoplasmic localization of optoTβRII before stimulation (B), and optoTβRII 
translocation to the plasma membrane in response to a short pulse of blue light 
stimulation (C).  
 
In the end, we successfully established Hela and HaCaT cell lines that stably 
express the optoTGFβ system (optoHela and optoHaCaT, respectively). The 
expression of optoTβRI, optoTβRII and iRFP-Smad2 proteins in these cell lines 
were validated by immunoblotting experiments (Figure 2.4.3). The expression 
level of iRFP-Smad2 is consistent with the expression level of the endogenous 
Smad2. The expression level of optoTβRI is not as high as the endogenous TβRI 
(around half of the endogenous TβRI); however the optoTβRII is much more than 
the endogenous TβRII (around 4 fold of its endogenous counterpart). The 
inconsistence of expression levels between the light controllable chimeric TGFβ 
receptors and the endogenous TGFβ receptors might come from two factors: (1) 
the abundances of the endogenous TGFβ receptors in Hela cells differ widely 
(Table 5.3-1), which is also confirmed by some preliminary results in our lab; (2) 
according to the design of the plasmid pLNCX2-optoTβRs, the transcription of 
both optoTβRI and optoTβRII share the same mRNA and are linked by a P2A 
bicistronic linker sequence, therefore the mRNA ratio of optoTβRI and optoTβRII 
should be around 1:1. However, due to the longer sequence (thus harder to be 
translated) and larger conformation (thus harder to fold correctly) of the PHR 
domain, the expression level of optoTβRII is usually much lower than that of the 
optoTβRI224. Taken together, the expression difference between the chimeric 
optoTβRs pair is smaller than that of the endogenous receptor pair. 
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After constructing the optoTGFβ system, we tried to characterize it in various 
aspects. First, we would like to make sure that TGFβ signaling in the optoTGFβ 
system could be triggered by light stimulation. As expected, upon blue light 
irradiation, plasma membrane translocation of optoTβRII and nuclear 
accumulation of Smad2 could be observed. In addition, the optoTGFβ system 
could also be activated by two-photon irradiation, which implies its deep-tissue 
application. Second, we would like to test if the light-induced TGFβ signaling 
could be blocked by receptor inhibitors. Since we didn’t modify the components 
of the endogenous TGFβ signaling pathway, we’d like to check if the endogenous 
TGFβ signaling is intact. As expected, the light-induced Smad2 activation can be 
specifically blocked by the TGFβ receptor inhibitor LY364947, and TGFβ ligand 
could induce Smad2 activation in the light-sensitive cells. Third, besides the 
subcellular translocation property of the proteins, we also want to test if the light-
activated Smad2 is indeed phosphorylated, and if the downstream target gene 
expression is also triggered by photoactivation. Moreover, we demonstrated that 
the blue light intensities we used in this study are not toxic to the cells. 
 
 
 
 3 
 Validation of the optoTGFβ System 
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To verify the functionality of the optoTGFβ system, we employed time-lapse 
microscopy to monitor the optoTGFβ system activation upon blue light 
stimulation. As expected, when illuminated with a short pulse of blue light (488 
nm, 12.4 μW), optoHela cells showed plasma membrane or nuclear translocation 
of optoTβRII or iRFP-Smad2, respectively (Figure 3.1.1 A). Quantification of the 
fluorescent signals in each channels was consistent with the observation (Figure 
3.1.1 B, C). This result confirms that blue light could activate the canonical TGFβ 
signaling in the optoTGFβ system. 
 
 
 
Figure 3.1.1  The optoTGFβs system: a light inducible switch to drive 
TGFβ/Smad signaling.  (A) Representative fluorescent images of optoTβRII 
(cytoTβRII-PHR-tdTomato, yellow) and iRFP-Smad2 (red) in optoHela cells, stimulated 
by a short pulse of blue light (488nm; pixel dwell time, 6.3 μs). Scale bar: 10 μm. (B-C) 
The mean intensity level of optoTβRII (B) or iRPF-Smad2 (C) fluorescence signal within 
the respective white squares marked in panel A.  
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Upon a short pulse of blue light stimulation, most optoTβRII arrived at the 
plasma membrane in 10 seconds, and gradually recovered in 10 minutes in the 
dark. The observed fast turn-on and relatively slow turn-off kinetics of the 
optoTGFβ system are consistent with the association and dissociation rates of the 
PHR-CIBN system170,215. As the photon excitation on the confocal laser scanning 
microscopy could reach the scale of subcellular level, these results suggest that 
the optoTGFβ system allows us to control and investigate TGFβ signaling at the 
single cell level. 
 
 β
The tissue penetration ability of blue light is poor, therefore it is very hard to 
access deep layer of cells in the tissue or thick specimens. This limits the use of 
blue light in experiments or applications that require deep penetration into living 
tissues or intact animal specimens. Multiphoton could overcome this limitation 
by using near-infrared excitation light to minimize scattering in the tissue, which 
enables not only dense living tissue penetration up to about one millimeter in 
depth, but also highly precise three-dimensional cell targeting. In addition, the 
lower-energy photons used in multiphoton experiments are less toxic, especially 
for those cells outside the focal volume225-227.  
Inspired by the work in which the PHR-CIBN module could be successfully 
activated by multi-photon stimulation170, we tried to test if our optoTGFβ system 
could also respond to multi-photon activation or not.  Using a chameleon laser 
with a power of 5.0 %, we found that Smad2 signaling could be triggered by 
several pulses of two-photon excitation at 860 nm (Figure 3.2.1). Compared with 
the blue light activation, the efficiency of multi-photon activation is much lower, 
as it needs longer illumination time for the same extent of Smad2 translocation. 
This is reasonable, as two-photon excitation only activates the light-sensitive 
proteins at the focal point or focal plane, the amount of proteins being activated 
during the multi-photon laser scanning process is far less than that by blue light 
stimulation.  
The above experiments of multi-photon microscopy indicate that TGFβ 
signaling can be activated by two-photon excitation in the optoTGFβ system. This 
suggests that it is possible to precisely control TGFβ signaling in living organisms 
with the optoTGFβ system, which further implies its potential medical 
applications.  
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Figure 3.2.1 The optoTGFβs system can be activated by two-photon 
excitation.  (A) Representative fluorescent images of optoTβRII (yellow) and iRFP-
Smad2 (red) in optoHela cells, excited by two-photon irradiation (860 nm).  Nuclear 
translocation of iRFP-Smad2 was observed. Scale bar: 10 μm. (B) Quantification of the 
nuclear iRFP-Smad2 (red signal) signaling dynamics in the two cells labeled in panel A. 
(C) Quantification of the redistribution dynamics of the corresponding optoTβRII signal. 
 
The successful activation by both blue light and two-photon stimulation 
indicates that the optoTGFβ system allows us to manipulate and study the TGFβ 
signaling at the single cell level, and even potentially in vivo. 
 
 β
β
LY364947 is a selective ATP-competitive, cell permeable inhibitor that blocks 
the kinase activity of both TβRI and TβRII228. As the cytoplasmic regions of both 
types of TGFβ receptors are retained in the optoTGFβ system, LY364947 should 
be able to inhibit the activity of both optoTβRI and optoTβRII. Indeed, when 
optoHela cells were cultured in the presence of LY364947, although blue light 
stimulation could still recruit optoTβRII to the plasma membrane through 
activating the PHR-CIBN module, iRFP-Smad2 did not translocate into the 
nucleus (Figure 3.3.1 A). This is because the kinase activity of the chimeric 
  
β β 45 
receptors was inhibited by LY364947 despite the receptor association, the 
receptors thus could no longer phosphorylate and activate Smad2. Therefore, the 
light-induced Smad2 activation of the optoTGFβ system can be specifically 
blocked by the selective inhibitor of TGFβ receptors (LY364947). 
Because we left the endogenous TGFβ signaling components unchanged, the 
endogenous TGFβ receptors are intact in optoHela or optoHaCaT cells. Moreover, 
the endogenous and chimeric TGFβ receptors are independent of each other. 
Therefore, TGFβ ligand should be able to induce iRFP-Smad2 activation in these 
cells via the endogenous TGFβ receptors. Indeed, when optoHela cells were 
treated with TGFβ1 in the dark, iRFP-Smad2 was activated and translocated into 
the nucleus, in the absence of the membrane recruitment of optoTβRII (Figure 
3.3.1 B).  
 
Figure 3.3.1  The responses of the optoTGFβ system to TGFβ receptor 
inhibitor and TGFβ ligand.  Representative fluorescent images of optoTβRII (yellow) 
and iRFP-Smad2 (red) in optoHela cells. (A) In the presence of TGFβ receptor kinase 
inhibitor LY364947, Smad2 didn’t translocate into nucleus, in spite of optoTβRII 
translocation induced by a short pulse of blue light (pixel dwell time, 6.3 μs). (B) Smad2 
nuclear translocation in response to 100 pM TGFβ1 ligand stimulation, independent of 
optoTβRII activation. Scale bars: 10 μm. 
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Blue light could be phototoxic when used at high intensities. Therefore, it is 
necessary to make sure the blue light intensity for optoTGFβ activation is low 
enough not to interfere with other cellular processes than the controllable TGFβ 
signaling activation. 
We employ both trypan blue staining and MTT assay to implement cell 
viability tests (Figure 3.4.1). In this experiment, both the un-transduced parental 
Hela cells and optoHela cells were irradiated in the 488nm LEDs illumination box 
(at the intensity of 0.8 mW/cm2) for 24 hours. In parallel, a same set of cells were 
kept in the dark, which were used as controls. The p-values calculated through a 
two-sample t-test indicated that, there is no significant difference of cell viability 
between the cells under 488nm illumination and the control cells in the dark. As 
the light intensities used to stimulate the optoTGFβ system in this project are 
always below 0.8 mW/cm2 (the intensity used in these cell viability assays), we 
could conclude that the blue light stimulations used in this study are not 
phototoxic to cells either expressing or not expressing the optoTGFβ system.  
 
 
Figure 3.4.1  Cell viability assays for parental Hela cells and optoHela 
cells after 24 hours of blue light stimulation (488 nm, 0.8 mW/cm2).  (A) results 
of the trypan blue stain assay, (B) results of the MTT cell viability assay. Error bars in (A) 
and (B) show the SEM (standard errors of the mean) from 6 and 16 replicates, 
respectively. The p-values were calculated using a 2-sample t-test.  
 
 
  
β 47 
 β
In the results above, we observed the nuclear translocation of iRFP-Smad2 
upon blue light stimulation, which implies the phosphorylation and activation of 
iRFP-Smad2 by the activated optoTβRs. To further confirm the functionality of 
the optoTGFβ system, we measured the phosphorylation levels of both the 
endogenous Smad2 and the transduced iRFP-Smad2 by western blotting 
experiments. 
Upon 100pM of TGFβ1 ligand stimulation, the phosphorylation level of the 
endogenous Smad2 increases immediately, and reaches the maximum level in 
one hour, then  gradually decreases. The time course of the endogenous Smad2 
phosphorylation in optoHela cells is similar to that in the parental Hela cells 
(Figure 3.5.1 A). This is confirmed by quantifying the relative P-Smad2 
(phosphorylated Smad2) level on the western blotting images (Figure 3.5.1 C). 
However, the phosphorylation dynamics of the chimeric iRFP-Smad2 lags 
slightly behind the endogenous one – while the endogenous P-Smad2 peaks at 
around one hour after adding TGFβ ligand, P-iRFP-Smad2 needs around two 
hours to reach its maximal level. The lower speed of iRFP-Smad2 
phosphorylation could be explained by the decreased phosphorylation efficiency, 
which might be due to the conformational change of Smad2 by the fluorescent 
tag, or simply due to the larger molecular construction of the iRFP-Smad2 protein. 
It could also be explained merely by the effect of iRFP-Smad2 overexpression. 
However, upon blue light stimulation, phosphorylation dynamics of iRFP-
Smad2 and the endogenous Smad2 are similar and consistent. The 
phosphorylation levels are increased and sustained upon blue light activation, 
although the phosphorylation of iRFP-Smad2 peaks slightly later than that of the 
endogenous Smad2 (Figure 3.5.1 B). Compared with the obvious difference 
between the endogenous Smad2 and iRFP-Smad2 dynamics in response to ligand 
stimulation, the smaller difference in the light stimulation experiments could be 
explained by the higher efficiency of light activation than ligand activation. 
Moreover, concerning the long-term TGFβ signaling behavior, the 
phosphorylation levels of both Smad2s sustain at the maximal levels even after 
eight hours of illumination (Figure 3.5.1 D), whereas they falls to around 50% of 
their maximal levels after eight hours of TGFβ ligand stimulation (Figure 3.5.1 C). 
This might be related to the negative regulations that are not functional in the 
optoTGFβ system. For example, the conformations of the chimeric optoTβRs are 
different from that of their endogenous counterparts, which help the optoTβRs 
evade the negative regulation. All these observations of Smad2 phosphorylation 
are consistent with the dynamics of iRFP-Smad2 nuclear translocation recorded 
by time-lapse live cell imaging. 
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Figure 3.5.1  Time course data of Smad2 phosphorylation dynamics in 
response to ligand or light activation.  (A) Representative western blots of P-Smad2 
(phosphorylated Smad2) time course in response to 100 pM TGFβ1 ligand stimulation, in 
optoHela and Hela cells. (B) Representative western blots of P-Smad2 time course in 
response to continuous blue light irradiation (488 nm, 0.8 Mw/cm2) in optoHela cells. (C) 
Quantification of the bands shown in panel A. (D) Quantification of the bands shown in 
panel B. Relative P-Smad2 level was calculated as the ratio of P-Smad2 to the 
corresponding Smad2 signal. All the data were normalized by the maximal signal of 
each time course. Error bars show the standard deviations from three replicates.  
 
In addition, phosphorylation of Smad2 upon various intensities of blue light 
stimulation is also tested. After setting the blue light of the LEDs illumination 
box to a specific intensity, optoHela cells were illuminated for 45 minutes before 
being subjected to immunoblotting analysis. Results showed that the 
phosphorylation levels of both the endogenous Smad2 and iRFP-Smad2 are 
consistent: they both increase gradually along with the increasing blue light 
intensity, but reach a plateau from the intensity of around 2 mW/cm2 (Figure 
3.5.2). These results suggest that, with the optoTGFβ system, the amplitude of 
Smad2 activation could be fine-tuned by modulating the power of illumination.  
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Figure 3.5.2  P-Smad2 responses upon various powers of blue light 
stimulations.  (A) Representative western blots for Smad2 signals in optoHela cells 
upon various intensities of blue light (488nm) irradiation, samples were collected at 45 
minutes after stimulation. (B) Quantification of the bands shown in panel A. Relative P-
Smad2 level was calculated as the ratio of P-Smad2 to the corresponding Smad2 signal. 
All the data were normalized by the maximal signal of each time course. Error bars show 
the standard deviations from three replicates.  
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Although the upstream TGFβ signaling (Smad2 phosphorylation and nuclear 
translocation) of the optoTGFβ system has been confirmed, its downstream gene 
expression activities still need to be evaluated. Here we chose Smad7229, TMEPAI 
(Prostate Transmembrane Protein, Androgen Induced 1)230, and PAI1 (Serpin 
Family E Member 1)231 as representatives. We implemented qPCR (quantitative 
PCR) experiments to check their respective mRNA levels at various time-points 
after blue light stimulation (Figure 3.6.1). For both Hela and HaCaT cells 
expressing the optoTGFβ system, blue light can efficiently induce the expression 
of the three downstream TGFβ responsive genes. 
 
 
 
Figure 3.6.1  The optoTGFβ system can induce the expression of TGFβ 
responsive genes.  Quantitative PCR assay for the expression of Smad7, TEMPAI and 
PAI1 genes in optoHela cells (left panels) and optoHaCaT cells (right panels) in response 
to blue light stimulation (488 nm, 4 mW/cm2). Samples were collected at 0, 1, 2 and 8 
hours after blue light irradiation in the LEDs box. The averages and standard deviations 
calculated from three replicates were plotted. 
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After characterizing the optoTGFβ system, in this chapter, we tried to 
quantitatively control the TGFβ signaling through manipulating blue light input 
for activating the optoTGFβ system. First, we would like to test the 
spatiotemporal controllability in the optoTGFβ system. We demonstrated that the 
optoTGFβ system enabled control of TGFβ signaling in single cells at high spatial 
and temporal resolution. Second, we would like to know if we can harness TGFβ 
signaling, and generate complex TGFβ signaling dynamics through manipulating 
the light input. As expected, by applying light stimulations of single pulse, 
frequent pulses and sparsely separated pulses, we generated transient, sustained 
and oscillated Smad2 signaling, respectively. Third, we made comparisons 
between light stimulation and ligand stimulation, in terms of the Smad2 
signaling activation dynamics. We found that with the optoTGFβ system, we 
could generate similar Smad2 dynamics by manipulating the light input, 
mimicking the patterns of ligand stimulation. Further than that, the optoTGFβ 
system expands the range of Smad2 activation by its ability to induce stronger 
Smad2 activation. 
 
 4 
Control of TGFβ Signaling  by the optoTGFβ System 
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In comparison with ligand stimulation, one of the largest advantages of light 
stimulation is the spatiotemporal control of stimulation at relatively high 
resolution. Since the laser beam on the confocal laser scanning microscopy could 
achieve high precision (i.e., at the subcellular level), the stimulation of the 
optoTGFβ system could be limited to specific single cells. In theory, only the 
light-sensitive proteins that are illuminated should be activated, hence only the 
portion of optoTβRII that is hit by the laser beam would undergo plasma 
membrane recruitment. Therefore, if we stimulate only one designate cell at a 
time, then only the optoTβRII proteins in this specific cell would translocate onto 
the plasma membrane and trigger the initiation of TGFβ signaling. In contrast, 
TGFβ signaling in other surrounding cells should stay inactive: no plasma 
membrane translocation of optoTβRII, and no nuclear translocation of iRFP-
Smad2, or the endogenous Smad2. 
To demonstrate the spatiotemporal control property of the optoTGFβ system, 
we implemented sequential light stimulation, and restricted the irradiation 
region to be in one specific cell by using a confocal laser scanning microscopy. At 
different time points (every 15 minutes), we irradiated one specific optoHela cell 
with a short pulse of blue light, while the surrounding cells were kept in dark 
(Figure 4.1.1). At time point 0 min, when we stimulated only the cell labeled as 
‘cell1’, only the iRFP-Smad2 in this specific cell was activated and started to 
translocate from the cytosol into the nucleus in the following several minutes 
(Figure 4.1.1 A, upper row). At time point 15 min, we similarly stimulated the 
cell labeled as ‘cell2’ and kept all the other cells in dark, only cell2 showed 
nuclear translocation of iRFP-Smad2 following this stimulation (Figure 4.1.1 A, 
middle row). We did the same stimulation to cell3 at time point 30min, and then 
observed its specific activation (Figure 4.1.1 A, lower row). During the whole 
experiment, cell4 and cell5 stayed in the dark and thus never had been activated, 
hence the distribution of iRFP-Smad2 in these two cells stayed the same. 
Quantification of the iRFP-Smad2 nuclear translocation (Figure 4.1.1 C) in each of 
the five cells confirms that Smad2 signaling was activated in each cell 
sequentially, in accordance with the same sequence of the pulsed blue light 
stimulation (Figure 4.1.1 B). This result suggests that it is possible to control the 
TGFβ signaling activation in single cells at high spatial and temporal resolution 
using the optoTGFβ system. 
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Figure 4.1.1  Spatiotemporal control of Smad2 signaling in optoHela 
cells.  (A) One short pulse of blue light (488 nm, 12.4 μW, pixel dwell time: 100 μs) was 
used to sequentially stimulate the yellow circular region of cell 1, cell 2 and cell 3 at 0 
min, 15 min and 30 min, respectively. Representative fluorescent images of iRFP-Smad2 
in optoHela cells showed specific and sequential nuclear Smad2 accumulation. (B) 
Schematic representation of the light stimulations for the cells marked in panel A. (C) 
Quantification of the nuclear Smad2 signaling dynamics of the cells labeled in panel A. 
Scale bar: 10 μm.   
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Compared with ligand stimulation, another advantageous property of light 
stimulation is enabling us to manipulate the pattern of input conveniently, and 
avoid medium change. Furthermore, with the optoTGFβ system, we could 
simultaneously monitor signaling dynamics of both optoTβRs and Smad2 in 
response to various light irradiation patterns.  
First, we implemented a single pulse stimulation (Figure 4.2.1 B). We 
stimulated the optoHela cells with a very short pulse of blue light (pixel dwell 
time: 3.15 μs/pixel, which is the time the focused laser dwells on each pixel). As 
shown both by video observation (Figure 4.2.1 A, yellow channel) and by image 
quantification (Figure 4.2.1 D), upon light irradiation, optoTβRII was 
immediately depleted from the cytosol, recruited to the plasma membrane, 
reaching the maximal extend of recruitment within seconds. After that, 
optoTβRII dissociated from the plasma membrane-localized optoTβRI and 
gradually returned to the cytoplasm, recovering to its pre-stimulation level 
within 15 min. In contrast, the Smad2 activation and deactivation processes were 
much slower. It took minutes for the Smad2 nuclear translocation to arrive its 
maximal level, and took hours for its recovery (Figure 4.2.1 A, red channel; 
Figure 4.2.1 C). Notably, although the amplitude of Smad2 signaling varies 
among individual cells, the peaking time of Smad2 nuclear accumulation is very 
robust, at about 20 min after the exposure to the short pulse of blue light. The 
deactivation of Smad2 was also much slower than the recovery of cytoplasmic 
optoTβRII signal. However, it is consistent with the relatively slow dynamical 
property of the Smad2 nuclear-cytoplasmic shuttling process133. These results also 
suggest that the dynamics of Smad2 signaling and TGFβ receptors activations 
occur on different time scales.  
As there is a delay of around 90 minutes between the Smad2 deactivation and 
the TGFβ receptors complex dissociation, we speculate that this delay feature 
would enable the TGFβ signaling pathway to remember the previous input 
signal and sustain the signaling for a short time. In this way, the TGFβ signaling 
could filter out input signal changes at high frequencies. To test this hypothesis, 
we monitored the TGFβ signaling dynamics in optoHela cells upon repeated 
pulses of blue light stimulation at high or low frequencies.  
When the cells were stimulated every 10 minutes (Figure 4.2.2 B), which is a 
period that is much shorter than the delay time between the receptors 
deactivation and the Smad2 deactivation, the Smad2 signaling showed a 
sustained response (Figure 4.2.2 A, red channel; Figure 4.2.2 C). Notably, the 
maximal level of Smad2 nuclear translocation in this experiment is generally 
much higher than that in single pulse stimulation experiments, and the time for 
peaking is also longer (around two hours after the first pulse of stimulation). This 
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is justified, as a single pulse doesn’t provide sufficient energy for a saturate 
Smad2 signaling, the effect of multiple pulses would accumulate until the 
saturation of signaling. Furthermore, as the phosphorylation level of Smad2 is 
correlated with the intensity of light input (Figure 3.5.2), the peaking time could 
vary depending on the total amount of light per unit of time a cell receives, i.e., 
the more intensive the illumination, the faster the Smad2 signaling would peak.  
As expected, when the cells were stimulated with pulsed light at a low 
frequency (Figure 4.2.3 B), an oscillated transient Smad2 signaling response was 
observed (Figure 4.2.3 A， red channel; Figure 4.2.3 C). As the activation of the 
light-sensitive module is reversible, the optoTβRII recruitment dynamics also 
showed an oscillated pattern (Figure 4.2.3 A, yellow channel; Figure 4.2.3 D). The 
period of Smad2 activation oscillation is in accordance with the period of input 
light pulses. Therefore, it is beyond dispute that we could generate other Smad2 
oscillations by manipulating the stimulation patterns, i.e., varying the frequency 
of input light pulses. 
In addition, it should be noted that, we did not implement continuous 
stimulation by live cell imaging. This is due to the nature of the laser scanning 
process of confocal microscopy, which operates on one single pixel at a time. 
Therefore it is in theory impossible to stimulate the entire image region 
simultaneously and continuously. However, as the continuous stimulation falls 
in the regime of highly frequent pulsed stimulation, the Smad2 signaling 
dynamics in response to continuous light stimulation should show a sustained 
response pattern, similar to the above response upon pulsed stimulation in high 
frequencies (Figure 4.2.2). 
Furthermore, depending on the dynamical properties of the downstream 
TGFβ responsive gene expressions, various patterns of TGFβ responsive 
transcription dynamics could also be generated by manipulate the light 
irradiation input. Cellular response in single cells could thus be adjusted 
accordingly. 
In summary, with the optoTGFβ system, we can easily generate three 
categories of Smad2 signaling dynamics: transient, sustained or oscillated, by 
modulating the patterns of blue light inputs. Moreover, by integrating these 
plentiful input patterns, we could further design more sophisticate light input 
patterns, and thus generate a variety of more complex Smad2 signaling dynamics, 
as well as a variety of TGFβ responsive gene expression dynamics. TGFβ 
signaling could therefore be better investigated, and the TGFβ signaling could 
also be better controlled in therapeutic applications. 
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Figure 4.2.1  Dynamics of Smad2 signaling upon one short pulse of 
blue light irradiation in the optoTGFβ system.  (A) Representative fluorescent 
images of optoTβRII (yellow) and iRFP-Smad2 (red) in optoHela cells in response to a 
pulse of 488nm light irradiation. Light power for the pulse: 12.4 μW. Pixel dwell time: 
3.15 μs. Scale bar: 10 μm. (B) Input pattern of the blue light stimulation. (C) 
Quantification of the nuclear Smad2 signaling dynamics in the cells labeled in panel A. 
(D) Quantification of the optoTβRII signaling dynamics shown in the cells labeled in 
panel A. 
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Figure 4.2.2  Dynamics of Smad2 signaling upon a highly frequent 
pulsed irradiation in the optoTGFβ system.  (A) Representative fluorescent images 
of optoTβRII (yellow) and iRFP-Smad2 (red) in optoHela cells in response to repeated 
pulses of 488nm light stimulation. Scale bar: 10 μm. Period of the pulses: 10 minutes. 
Light power for each pulse: 12.4 μW. Pixel dwell time: 3.15 μs. (B) Input pattern of the 
blue light stimulation. (C) Quantification of the nuclear Smad2 signaling dynamics in the 
cells labeled in panel A. (D) Quantification of the optoTβRII signaling dynamics shown 
in the cells labeled in panel A. 
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Figure 4.2.3  Dynamics of Smad2 signaling upon a low frequent 
pulsed irradiation in the optoTGFβ system.  (A) Representative fluorescent images 
of optoTβRII (yellow) and iRFP-Smad2 (red) in optoHela cells in response to 3 pulses of 
488nm light stimulation. Scale bar: 10 μm. Period of the pulses: 3 hours. Light power for 
each pulse: 12.4 μW. Pixel dwell time: 3.15 μs. (B) Input pattern of the stimulation. (C-D) 
Quantification of the nuclear Smad2 signaling dynamics (C) or the optoTβRII signaling 
dynamics (D) in the cells labeled in panel A.  
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Although both blue light and TGFβ ligand could induce Smad2 signaling, we 
still need to check whether blue light stimulation mimics similar TGFβ ligand 
stimulation for Smad2 signaling activation, i.e., we would like to know whether 
the Smad2 signaling dynamics upon the two different kinds of stimulations are 
similar when the input patterns are similar. Here we planned to check the Smad2 
signaling in response to both kinds of stimulations in three types of input 
patterns: single pulse, frequent pulses and infrequent pulses. 
For results of TGFβ ligand stimulation, due to the necessity of double medium 
changes for every pulsed stimulation, it is very inconvenient to implement 
pulsed ligand stimulation, especially for pulses at high frequencies. Therefore, 
here we tried to use a published mathematical model to predict the Smad2 
signaling in response to the three patterns of TGFβ stimulations: single pulse, 
pulses with a period of 10 minutes, and pulses with a period of 3 hours (Figure 
4.3.1 A-C, upper panels). The Smad2 dynamics are predicted to be transient, 
sustained and oscillated with a period of 3 hours, respectively (Figure 4.3.1 A-C, 
lower panels). 
For results of blue light stimulation, through time-lapse live cell imaging, we 
stimulated optoHela cells with the three patterns of light input: one single pulse, 
one pulse in every 10 minutes, and one pulse in every 3 hours (Figure 4.3.1 D-F, 
upper panels). The iRFP-Smad2 signaling dynamic responses in dozens of 
individual cells were recorded and quantified subsequently. 
Despite the variations of Smad2 signaling among individual cells in response 
to the same blue light stimulation, the Smad2 signaling dynamics in optoHela 
cells showed transient, sustained or oscillated responses upon light stimulation 
patterns of single pulse, frequent pulses or infrequent pulses, respectively 
(Figure 4.3.1 D-F, lower panels). These results are consistent with the Smad2 
dynamic responses upon the corresponding input patterns of TGFβ ligand 
stimulation, which were experimentally measured or theoretically predicted at 
the population level (Figure 4.3.1 A-C, lower panels) 136,232,233. Therefore, with 
similar stimulation input pattern, light and ligand induce similar dynamics of 
Smad2 signaling responses. 
We therefore conclude that similar patterns of light stimulation or TGFβ 
ligand stimulation would induce similar dynamics of Smad2 signaling 
activations. 
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Despite the fact that the static cellular structures encode substantial 
information about biological functions, more and more studies suggest that 
biological information is also encoded in another dimension: dynamics of 
signaling over time216. The dynamics of signaling is the pattern of signal changes 
over time, and the ‘signal’ could be any aspect, such as molecular concentration, 
chemical modification, and translocation, etc217. Examples for the measurable 
features of signaling dynamics are: delay (the duration from the stimulation until 
the onset of activation), duration of activation, duration of peak retention, 
duration of deactivation, cumulative level, amplitude and frequency, etc. (Figure 
4.3.2). Needless to say, these temporal codes enormously extend the complexity 
of the cellular information. Therefore, decoding and controlling the dynamics of 
signaling are important for investigating and modulating the related cellular 
functions. 
 
Figure 4.3.2 Illustration for some measureable features of signaling 
dynamics.  Delay is the duration from the stimulation until the onset of activation; 
Activation is the duration between the onset of activation and the time when reaching 
the maximal level; Duration is the time range of peak retention; Deactivation is the 
duration of signal decreasing; Amplitude is the maximal level of activation a signal 
could reach; Frequency is the duration between consecutive peaking time; cumulative 
level is the total accumulated signal, i.e., the area under the curve of signal dynamics. 
In this study, cells expressing the optoTGFβ system contain two versions of 
TGFβ receptor pairs: one is the endogenous pair, which responds to TGFβ 
ligands in the surrounding medium; the other is the chimeric optoTβRs pair, 
which responds exclusively to blue light irradiation. Though both of these two 
receptor pairs induce similar downstream signaling transmission pathways, 
when discerning carefully, we could find that there exist differences between the 
dynamics induced by TGFβ ligand and that by blue light, even for similar 
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patterns of stimulation input. Upon blue light stimulation, most of the Smad2 
could translocate into the nucleus (Figure 4.3.3 B). In contrast, there were still 
observable traces of Smad2 remaining in the cytosol at the maximal level of 
response (~ 60 minutes after stimulation), even though the cells are treated with a 
saturating dose (100 pM) of TGFβ ligand (Figure 4.3.3 A) 136,234. Quantification 
confirms this observation. While the nuclear-to-cytoplasmic (N2C) ratio of iRFP-
Smad2 upon blue light stimulation could reach higher than 10, it was less than 4 
in the case of ligand stimulation (Figure 4.3.3 D). In addition, when checking the 
raw data, intensities of the cells in this experiment were at the same scale (Figure 
4.3.3 C), which means the abundances of iRFP-Smad2 in the representative cells 
were similar and thus comparable. These results suggest that blue light could 
induce stronger Smad2 nuclear translocation. 
Besides the difference of amplitude, the speed of activation, i.e. the time 
needed to peak the activation is also different between TGFβ ligand and blue 
light stimulation. While in response to blue light stimulation, iRFP-Smad2 could 
translocate to the maximal extend in less than 20 minutes, the peaking time of 
iFRP-Smad2 translocation upon TGFβ ligand stimulation was around one hour. 
And there was still a large amount of iRFP-Smad2 in the cytoplasmic region 15 
minutes after adding a saturating dose of TGFβ ligand (Figure 4.3.3 A, left 
panels). Therefore, blue light could induce faster Smad2 activation.  
These differences might be resulted from the different molecular regulations 
on the specific responsive receptor pair, which is in turn determined by its 
specific molecular mechanism. For example, negative feedback regulations might 
have different impacts on the endogenous and light-controllable TGFβ signaling. 
In the endogenous system, TGFβ ligand binds to TβRII which then recruits and 
phosphorylates TβRI, the activated TβRI then activates Smads. During this time, 
the negative feedbacks gradually build up and act on receptors or Smads to 
maintain the signaling at a certain level. However, in the optoTGFβ system, light 
induces a much faster reaction of receptor binding and activation, which 
immediately activates Smad2 to a higher extent before the negative regulations 
are building up. In addition, due to the chimeric structures of optoTβRs, negative 
feedbacks regulating the endogenous TβRs might fail to regulate optoTβRs. 
Therefore the TGFβ signaling could reach a higher level in the optoTGFβ system. 
On the one hand, the stronger Smad2 signaling induced in the optoTGFβ 
system in turn reveals the effects of negative regulations in the endogenous TGFβ 
signaling. On the other hand, due to the convenient control of the optoTGFβ 
system, it is easy to generate any TGFβ signaling dynamics that the TGFβ ligand 
could trigger, through adjusting the input light intensity or stimulation pattern. 
Therefore, the optoTGFβ system provides a wider range of signaling activation, 
which we could apply to modulate TGFβ signaling in specific cells. 
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Figure 4.3.3 optoTβRs could induce stronger Smad2 signaling.  optoHela 
cells were stimulated by 100pM TGFβ (Cell1 and Cell2), or illuminated by a single pulse 
of blue light (Cell3 and Cell4; light: 488 nm, 12.4 μW, with pixel dwell time of 3.15 μs). 
Representative image of iRFP-Smad2 localization after 15 minutes, 1 hour of TGFβ 
stimulation (A) or a pulse of blue light stimulation (B). Yellow signal: optoTβRII; red 
signal: iRFP-Smad2. Scale bar: 10 μm. (C) Quantification of the mean iRFP-Smad2 signal 
in both nuclear and cytoplasmic compartments, in the cells labeled on panel A. Cell1 and 
Cell2 were quantified for the 60 minute timepoint after TGFβ ligand stimulation; Cell3 
and Cell4 at the 15 minute timepoint after blue light stimulation were quantified. 
Regions without cells were measured as background signal. (D) Normalized iRFP-
Smad2 signal in the cells as on panel C. Intensities of both nuclear and cytoplasmic iRFP-
Smad2 were subtracted by the corresponding background intensity, and then 
normalized by the cytoplasmic signal of the corresponding cell.  
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To better describe the dynamic properties of the optoTGFβ system, and to 
facilitate further applications of the optoTGFβ system, in this chapter, we 
formulated a mathematical model by integrating a light controllable module to a 
previously developed model of the endogenous canonical TGFβ/Smad signaling. 
As the previous models were built on experimental datasets of HaCaT cells, 
whose physiological background is not exactly the same as Hela cells which were 
used in our project, we calibrated our new model with fresh quantitative 
experimental datasets based on Hela or optoHela cells. 
One thing we’d like to point out here is that, compared with the previous 
model calibration processes, we obtained quantitative data more efficiently and 
precisely by the optoTGFβ system. Therefore, the optoTGFβ system facilitates 
mathematical model development, and further promotes better characterization 
of TGFβ signaling. 
After model construction and parameter estimation, we validated the model 
performance by assessing in-sample fit and out-sample fit. Taking the advantages 
of model simulation, we scanned several parameters to explore several 
characteristics of the optoTGFβ system. These were then followed by a summary 
of the model.  
 5 
 Development of a Mathematical Model for the optoTGFβ System 
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The chimeric optoTGFβ system (Figure 5.1.1) was generated from two 
different systems: the light responsive protein pair that controls the activity of the 
receptors (optoTβRs), and the downstream TGFβ signaling. Therefore, the model 
contains 2 major parts: 
I. The optoTβRs activation and deactivation, including: 
a. The optoTβRII activation (transformation of the light-sensitive domain 
PHRi → PHRa by light irradiation)； 
b. Activated optoTβRII forms receptors complex (optoRC) with optoTβRI； 
c. The optoRC dissociation; 
II. The Smads activation and deactivation, including: 
a. The nucleocytoplasmic shuttling of Smad2/Smad4; 
b. The association and dissociation of Smad2/Smad4; 
c. The phosphorylation and dephosphorylation of Smad2. 
 
Figure 5.1.1  Schematic model of the optoTGFβ system. optoRC, 
activated optoTβRs complex; pSmad2n, phosphorylated Smad2 in the nucleus; etc. It 
should be noted that the cytoplasmic region of TβRII in optoTβRII is constitutively active 
for activating TβRI. It is the light-sensitive PHR domain in optoTβRII that is activated by 
light irradiation, followed by association with the binding partner, i.e., CIBN in 
optoTβRI. 
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I. The optoTβRs complex formation upon light activation is very fast and 
reaches its maximum within one minute. It should be noted here that the 
cytoplasmic region of TβRII in optoTβRII is constitutively active for 
activating TβRI. It is the light-sensitive PHR domain in optoTβRII that is 
activated by light stimulation, which then binds with its partner, i.e., CIBN 
in optoTβRI. When we stimulated optoHela cells with a short pulse (< 1 s) 
of blue light, we could observe a depletion process of optoTβRII from the 
cytoplasmic region during the first minute after the stimulation (Figure 
5.3.1). This indicates that, to model the light activation, there are clearly two 
steps that we should describe separately:  
1) a very fast reaction of optoTβRII activation by light stimulation;  
2) a relatively slow reaction of optoTβRs association to form the 
optoTβRs complex (optoRC).  
As the TGFβ signaling in the optoTGFβ system saturates for light intensities 
above a certain threshold (Figure 3.5.2), we assume a Michaelis-Menten 
kinetic for the optoTβRII activation step, which transforms the inactivate 
optoTβRII pool (ioptoT2R) to a pool of activated optoTβRII (optoT2R). Its 
two parameters (𝑉𝑚𝑎𝑥 and 𝐾𝑀) could be assigned arbitrarily as long as all of 
optoTβRII could be activated within 1 second upon a saturating light 
intensity. Here, we assigned the two parameters (Table 5.3-2) by assuming 
that a light intensity of 1 (with an arbitrary unit) could activate over 90 
percent of the inactivate optoTβRII pool (ioptoT2R) in one second. The 
optoTβRs association step was modeled by mass action kinetic, just as the 
rest reactions in the model. 
II. Being in accordance with Zi’s model, we assumed that the phosphorylation 
rate of Smad2 is proportional to the concentration of the cytoplasmic Smad2 
and the activated optoTβRs complex (optoRC). Besides, we also assumed 
that dephosphorylation only happens in the nucleus as there is little 
cytoplasmic phosphatase activity targeting Smads complex133. 
III. Similar to the previous models133,136, we assumed Smad3 undergoes the 
same reactions as Smad2, and therefore omitted Smad3 in the model. 
IV. As the total amount of optoTβRs and Smad2 proteins varied little in the 
time scale of our experiment, independent of the presence or absence of 
perturbation. We assumed the amounts of all the proteins involved in the 
model are constant. Although degradation and production exist in the cell, 
they are in balance. Therefore, for simplification, production and 
degradation of all the proteins were not explicitly modeled in this model. 
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Table 5.2-1 Equations of the mathematical model 
Ordinary differential equations* 
Receptor Module 
d[optoT2R]
d𝑡
 = 
𝑉𝑚𝑎𝑥 [Light]
𝐾𝑀 + [Light]
 [ioptoT2R] – 𝑘𝑜𝑛
𝑜𝑝𝑡𝑜𝑇𝑅𝑠 [optoT1R] [optoT2R] 
d[ioptoT2R]
d𝑡
 = 𝑘𝑑𝑖𝑠𝑠
𝑜𝑝𝑡𝑜𝑇𝑅𝑠  [optoRC] – 
𝑉𝑚𝑎𝑥 [Light]
𝐾𝑀 + [Light]
 [ioptoT2R]  
d[optoRC]
d𝑡
 = 𝑘𝑜𝑛
𝑜𝑝𝑡𝑜𝑇𝑅𝑠 [optoT1R] [optoT2R] – 𝑘𝑑𝑖𝑠𝑠
𝑜𝑝𝑡𝑜𝑇𝑅𝑠 [optoRC] 
d[optoT1R]
d𝑡
 = 𝑘𝑑𝑖𝑠𝑠
𝑜𝑝𝑡𝑜𝑇𝑅𝑠
  [optoRC] – 𝑘𝑜𝑛
𝑜𝑝𝑡𝑜𝑇𝑅𝑠
 [optoT1R] [optoT2R] 
Smad Module 
d[S2𝑐]
d𝑡
 = 
Vnuc
Vcyt
 𝑘𝑒𝑥𝑝𝑆2  [S2𝑛] – 𝑘𝑖𝑚𝑝𝑆2  [S2𝑐] – 𝑘𝑝ℎ𝑜𝑠𝑆2  [S2𝑐] [optoRC]  
d[S2𝑛]
d𝑡
 =  
𝑉𝑐𝑦𝑡
𝑉𝑛𝑢𝑐
 𝑘𝑖𝑚𝑝𝑆2  [S2𝑐] – 𝑘𝑒𝑥𝑝𝑆2  [S2𝑛] + 𝑘𝑑𝑒𝑝ℎ𝑜𝑠𝑆2  [pS2𝑛] 
d[S4𝑐]
d𝑡
 = 
𝑉𝑛𝑢𝑐
𝑉𝑐𝑦𝑡
 𝑘𝑒𝑥𝑝
𝑆4  [S4𝑛] – 𝑘𝑖𝑚𝑝
𝑆4  [S4𝑐] + 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 [pS2S4𝑐] –  𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠 [S2𝑐] [S4𝑐] 
d[S4𝑛]
d𝑡
 = 
𝑉𝑐𝑦𝑡
𝑉𝑛𝑢𝑐
  𝑘𝑖𝑚𝑝
𝑆4  [S4𝑐] – 𝑘𝑒𝑥𝑝
𝑆4  [S4𝑛] + 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 [pS2S4𝑛] –  𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠 [pS2𝑛] [S4𝑛] 
d[pS2𝑐]
d𝑡
= 
𝑉𝑛𝑢𝑐
𝑉𝑐𝑦𝑡
 𝑘𝑒𝑥𝑝
𝑆2  [pS2𝑛] – 𝑘𝑖𝑚𝑝
𝑆2  [pS2𝑐] + 𝑘𝑝ℎ𝑜𝑠
𝑆2  [S2𝑐] [optoRC]  
                         – 𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠 [pS2𝑐] [S4𝑐] + 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 [pS2S4c]  
                         – 2 𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠 [pS2𝑐] [pS2𝑐] + 2 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 [pS2S2c] 
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d[pS2n ]
d𝑡
 = 
𝑉𝑐𝑦𝑡
𝑉𝑛𝑢𝑐
  𝑘𝑖𝑚𝑝
𝑆2  [pS2𝑐] – 𝑘𝑒𝑥𝑝
𝑆2  [pS2𝑛 ] – 𝑘𝑑𝑒𝑝ℎ𝑜𝑠
𝑆2  [pS2𝑛] 
                           + 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 [pS2S4n] – 𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠 [pS2𝑛] [S4𝑛]  
                           + 2 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 [pS2S2𝑛] – 2𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠 [pS2𝑛] [pS2𝑛] 
d[pS2S2c]
d𝑡
 = 𝑘𝑜𝑛𝑆𝑚𝑎𝑑𝑠 [pS2𝑐] [pS2𝑐] – 𝑘𝑜𝑓𝑓𝑆𝑚𝑎𝑑𝑠 [pS2S2c] – 𝑘𝑖𝑚𝑝𝑆𝑚𝑎𝑑𝑠 [pS2S2c] 
d[pS2S2𝑛]
d𝑡
= 
𝑉𝑐𝑦𝑡
𝑉𝑛𝑢𝑐
 𝑘𝑖𝑚𝑝
𝑆𝑚𝑎𝑑𝑠 [pS2S2c] – 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 [pS2S2𝑛] + 𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠 [pS2𝑛] [pS2𝑛] 
d[pS2S4c ]
d𝑡
 = 𝑘𝑜𝑛𝑆𝑚𝑎𝑑𝑠 [pS2𝑐] [S4𝑐] – 𝑘𝑜𝑓𝑓𝑆𝑚𝑎𝑑𝑠 [pS2S4c] – 𝑘𝑖𝑚𝑝𝑆𝑚𝑎𝑑𝑠 [PS2S4c] 
d[pS2S4n]
d𝑡
 = 
𝑉𝑐𝑦𝑡
𝑉𝑛𝑢𝑐
 𝑘𝑖𝑚𝑝
𝑆𝑚𝑎𝑑𝑠 [pS2S4c] – 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 [pS2S4n] + 𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠 [pS2𝑛] [S4𝑛] 
Assignment rules and compartment parameters 
Smad2N2C = 
[S2n] + [pS2n ] + 2 [pS2S2n] + [pS2S4n]
[S2𝑐] + [pS2c] + 2 [pS2S2c] + [pS2S4c]
 
pSmad2totalAmount = ([pS2𝑛] + 2 [pS2S2n] + pS2S4n ))*602   
                          + ([pS2c] + 2 [pS2S2c] +[pS2S4c]) *2.66*602 
 
* See tables Table 5.3-2 and Table 5.3-3 for annotation of each parameters and 
species, respectively. 
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Model parameters were estimated either by experimental measurement, or by 
data fitting. Some parameters could be easily measured through experimental 
approaches available in our lab; several others could be inferred by referring to 
the literature or public databases. The remaining four parameters, which were 
hard to access directly through experimental measurement, were estimated 
through data fitting. We generated three independent experimental datasets by 
live cell imaging, and quantified the iRFP-Smad2 signal in both nuclear and 
cytoplasmic region in multiple cells at various time points. These data were used 
to estimate the four parameters. After that, another two new datasets were used 
for model validation. 
The model frame of the second part was based on the model developed by Zi 
et al136, however, the physiological background of Hela cell is different from that 
of HaCaT cell, upon which Zi’s model was built. Therefore, we used different 
parameters, which were determined in this work through experimental 
measurement or parameter estimation. 
 
 
 
A typical Hela cell has a diameter of 20 microns235 (consistent with the image 
observations in this study). Considering the ratio of cytoplasmic-to-nuclear 
volume estimated in the following section 5.3.1.5 (~ 2.66), the volumes of nucleus 
and cytoplasm could be estimated as 1 pl (picoliter, = 1×10-12 L) and 2.66 pl, 
respectively. 
 
 
Concentrations of all the relevant endogenous proteins were estimated by 
referring to GeneCards236 and MaxQB237 databases, which include numerous 
protein expression data measured in Hela cells. Concentrations of the chimeric 
proteins in the optoTGFβ system were estimated by comparing to their 
respective endogenous counterparts on western blots. 
Here we used the relative expression value measured as ppm (parts per 
million). By considering the protein density for a typical mammalian cell of 
2.6*106 proteins/um3 238, concentrations of the corresponding proteins could be 
estimated accordingly. 
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Table 5.3-1 Definition of the protein concentrations at steady state 
Name 
Rel. 
Expression 
(ppm) 
Concentration 
(nM) 
Surface 
(nM) 
Cytoplasm 
(nM) 
Nucleus 
(nM) 
TβRI 16 71.74 7.17* 64.56 0 
TβRII 0.55 2.47 0.25* 2.22 0 
Smad2 58 260.05 0 291.32 176.87 
Smad4 22 98.64 0 61.4 197.7 
optoTβRI TβRI * 0.55 39.46 39.46 0 0 
optoTβRII TβRII * 3.6 8.88 0 8.88 0 
iRFP-
Smad2 
Smad2 * 1.7 442.08 0 495.24 300.68 
* Calculated by referring to the estimation that around 10 percentages of TGFβ 
receptors locate on the plasma membrane108,136. 
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The kinetic parameter for the optoTβRs association (𝑘𝑜𝑛
𝑜𝑝𝑡𝑜𝑇𝑅𝑠) was measured 
by frequent imaging of the optoTβRII signal following a pulsed stimulation. 
Briefly, optoHela cells were stimulated by a short pulse of blue light, images of 
the optoTβRII channel were taken before and after the light stimulation at a 
frequency of 2s-per-image (Figure 5.3.1 A). Dynamics of the cytoplasmic 
optoTβRII signal depletion in multiple cells were quantified and fitted to a mass 
action kinetic ODE (Figure 5.3.1 B), using the Curve Fitting Toolbox in MATLAB. 
The association parameter could therefore be obtained (Figure 5.3.1 C).  
Specifically, the optoTβRs association process is at the scale of seconds, while 
the activation of optoTβRII is super fast (at the scale of ~us), and the dissociation 
process of optoRC (the optoTβRs complex) is slow (at the scale of minutes). We 
assumed that optoTβRII is immediately activated and the dissociation of optoRC 
could be ignored during the first minute after light activation. Therefore, we 
could use a mass action kinetic ODE to describe the optoTβRs association process: 
 
d𝑥
d𝑡
 =  − 𝑘𝑜𝑛 ∙ 𝑥 ∙ (𝑥 + 𝑑) (1) 
Where 𝑥 denotes the concentration of cytoplasmic optoTβRII, (𝑥 + 𝑑) denotes 
the concentration of optoTβRI, and 𝑑  denotes the difference between the 
concentration of optoTβRII and optoTβRI. 𝑑 could be calculated by: 
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 𝑑 =  𝑥0 ∙  (𝑅 − 1) (2) 
Where 𝑥0 denotes the initial level of 𝑥, 𝑅 denotes the ratio of (the concentration 
of) optoTβRI to optoTβRII, which could be calculated by referring to Table 5.3-1.  
Solving the ODE (1), we can get: 
 𝑥𝑡 =  
𝑑
𝑒
ln(
𝑑+ 𝑥0
𝑥0
) + 𝑑 ∙ 𝑘𝑜𝑛 ∙ 𝑡
 − 1
 (3) 
By live cell imaging and image quantification, we could get a series of 𝑥𝑡with 
the corresponding t. By fitting these data to function (3), the parameter 𝑘𝑜𝑛 could 
be obtained, which is the kinetic parameter for optoTβRs association (𝑘𝑜𝑛
𝑜𝑝𝑡𝑜𝑇𝑅𝑠). 
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Figure 5.3.1  Determination of the optoTβRs association kinetics.  
optoHela cells were stimulated by a short pulse of blue light, images for the optoTβRII 
channel were taken at a frequency of 2s-per-image, the quantified optoTβRII dynamics 
were fitted to obtain the association parameter. (A) Representative images of optoTβRII 
translocation onto the plasma membrane upon light stimulation. Upper panels, from left 
to right, t=30 sec before, t= 2 sec, t=4 sec after photoactivation; lower panels, from left to 
right, t=6 sec, 10 sec, 60 sec after photoactivation. Scale bar: 10µm. (B) Quantification of 
cytoplasmic optoTβRII intensity in multiple cells over time (open circles). Data were 
normalized by subtracting the corresponding intensities when reaching the highest 
recruitment. Activation was done at the time point 0. In the corresponding color, are the 
fitted curves. (C) Boxplot of the optoTβRs association kenitics from the fits in (B). 
 
 β
The kinetics of optoTβRs dissociation ( 𝑘𝑑𝑖𝑠𝑠
𝑜𝑝𝑡𝑜𝑇𝑅𝑠 ) was determined by 
quantifying images of optoTβRII signal following a pulsed stimulation, with a 
longer time scale. Briefly, optoHela cells were stimulated by a short pulse of blue 
light, images of the optoTβRII channel were taken before and after the light 
stimulation at a frequency of 30s-per-image (Figure 5.3.2 A). After that, the 
dynamics of the cytoplasmic optoTβRII signal recovery in multiple cells were 
quantified and fitted to an exponential decay function (Figure 5.3.2 B), using the 
Curve Fitting Toolbox in MATLAB. Therefore the dissociation parameter could 
be obtained (Figure 5.3.2 C). 
Specifically, the association of optoTβRs reaches the maximal extent in 1 
minute after a pulse of light stimulation, after that, the dissociation of optoRC 
dominates. Therefore, we could use a first-order mass action kinetic ODE to 
describe this optoTβRs dissociation process: 
 
d𝑥
d𝑡
 =   𝑘𝑑𝑖𝑠𝑠 ∙ (𝑥𝑡𝑜𝑡 − 𝑥) (4) 
Where 𝑥  denotes the concentration of cytoplasmic optoTβRII, (𝑥𝑡𝑜𝑡 −
𝑥) denotes the concentration of optoRC, i.e., the portion of optoTβRII in optoRC 
at the plasma membrane, and 𝑥𝑡𝑜𝑡 denotes the total amount of optoTβRII, which 
is the concentration of cytoplasmic optoTβRII at the steady state in the dark.  
Solving the ODE (4), we can get: 
 𝑥𝑡 =  𝑥𝑡𝑜𝑡 +  𝑒−𝑘𝑑𝑖𝑠𝑠 ∙ 𝑡  ∙  (𝑥0  −  𝑥𝑡𝑜𝑡) (5) 
By live cell imaging, we could get a series of 𝑥𝑡with the corresponding t (we 
used the data between 1min and 10min after photoactivation). By fitting these 
data to function (5), the parameter 𝑘𝑑𝑖𝑠𝑠 could be obtained, which is the kinetic 
parameter for optoTβRs dissociation (𝑘𝑑𝑖𝑠𝑠
𝑜𝑝𝑡𝑜𝑇𝑅𝑠). 
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Figure 5.3.2  Determination of the optoTβRs dissociation kinetics.  
optoHela cells were stimulated by a short pulse of blue light, dynamics of the optoTβRII 
signal were quantified and fitted to obtain the dissociation parameter. (A) 
Representative images of optoTβRII translocation onto the plasma membrane upon light 
stimulation, and its recovery afterwards. Upper panels, from left to right, t=1 min before, 
t= 10s, t=1 min after photoactivation; lower panels, from left to right, t=4 min, t= 6 min, 
t=10 min after photoactivation. Scale bar= 20µm. (B) Quantification of the optoTβRII 
signal in multiple cells over time (open circles). Data were normalized by the respective 
initial intensities (at 1min after photoactivation). Activation was done at the 0 minute 
time point. In the corresponding color, are the fitting curves according to the optoTβRs 
dissociation model. (C) Boxplot of the characteristic parameter of optoTβRs dissociation 
from the fits in (B). 
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While western blotting data indicate the total amounts of specific proteins, 
fluorescent protein intensities quantified on microscopic images indicate the 
concentrations of the corresponding proteins. To parallelize and compare these 
two types of data, cell volume is needed additionally. While it is difficult to infer 
the volume of either nuclear or cytoplasmic compartment by western blotting 
experiments, it is possible to measure the volumes of these two compartments by 
microscopy. Then the total amount of a specific protein could be calculated by 
converting the concentration data of both compartments, which could match the 
western blotting data. To simplify the experiments, rather than measuring the 
exact physical data of the volumes, we could get the ratio of the accessible 
cytoplasmic-to-nuclear volume by using the already available data collected in 
most of the live-cell imaging experiments in this study. 
During the process of fluorescence-tagged Smad2 translocation from the 
cytosol into the nucleus, an increase of the fluorescence signal in the nuclear 
compartment (∆Fnuc) is companioned by a decrease of the fluorescent signal in the 
corresponding cytoplasmic compartment (∆Fcyto). The total flux of the iRFP-
Smad2 could be written as: 
 ∆𝐽𝑆𝑚𝑎𝑑2 = ∆𝐹𝑛𝑢𝑐  ∙ 𝑉𝑛𝑢𝑐   =  − ∆𝐹𝑐𝑦𝑡  ∙ 𝑉𝑐𝑦𝑡 (6) 
where 𝑉𝑛𝑢𝑐  and 𝑉𝑐𝑦𝑡𝑜 are the volumes of the accessible nuclear and cytoplasmic 
compartments, respectively. Therefore, the ratio of the accessible cytoplasmic-to-
nuclear volume could be calculated by: 
 𝑅 = 𝑉𝑐𝑦𝑡 𝑉𝑛𝑢𝑐⁄    = − ∆𝐹𝑛𝑢𝑐 ∆𝐹𝑐𝑦𝑡⁄  (7) 
To determine the accessible cytoplasmic-to-nuclear volume ratio for Hela cells, 
here we chose the one-hour-long live cell imaging data for optoHela cells upon a 
short pulse of blue light stimulation. Images of the iRFP-Smad2 channel were 
taken before and after the light stimulation, recording the process of Smad2 
nuclear translocation. The Smad2 signal in both the nuclear and the cytoplasmic 
regions were quantified at various time points. For each specific cell, the nuclear 
iRFP-Smad2 signal difference between two random time points was calculated as 
∆𝐹𝑛𝑢𝑐, the corresponding change of the cytoplasmic Smad2 signal was calculated 
as ∆𝐹𝑐𝑦𝑡, then the ratio of them was calculated by 𝑅 = − ∆𝐹𝑛𝑢𝑐 ∆𝐹𝑐𝑦𝑡⁄  to represent 
the ratio of the accessible cytoplasmic-to-nuclear volume for this specific cell 
(Figure 5.3.3 A). After calculating for various time point pairs and for various 
cells, we obtained a value of 2.66 +/- 0.02 (Figure 5.3.3 B), which is a reasonable 
result, and in good agreement with other studies133. 
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Figure 5.3.3  Determination of the accessible cytoplasmic-to-nuclear 
volume ratio.  optoHela cells were stimulated by a short pulse of blue light, dynamics 
of the Smad2 signal in both the nuclear and the cytoplasmic regions were quantified. The 
ratio of their changes was calculated as 𝑅 = − ∆𝐹𝑛𝑢𝑐 ∆𝐹𝑐𝑦𝑡⁄  to represent the ratio of the 
accessible cytoplasmic-to-nuclear volume for the corresponding cell, which was 
represented as a red circle on the panel (A).  (B) Boxplot of the 𝑅 (ratios of accessible 
cytoplasmic-to-nuclear volume) for multiple time point pairs (~ 10 timepoints) for 
multiple cells (141 cells) as represented on the panel (A). The typical 𝑅 is 2.66 +/- 0.02. 
 
 
To estimate the import and export rate constants for the constitutive shuttling 
processes of iRFP-Smad2, we implemented whole compartment FRAP of nuclear 
iRFP-Smad2. In the absence of stimulation, optoHela cells stay in a steady state 
where only the basal nucleocytoplasmic shuttling of Smads is taking place. 
Photobleaching of the nuclear localized iRFP-Smad2 disturbs this steady state, 
and the ratio of nuclear-to-cytoplasmic (N2C) fluorescence will recover to the 
steady state due to the basal nucleocytoplasmic shuttling of Smads. Nuclear 
importing and exporting rates (𝑘𝑖𝑚𝑝 and 𝑘𝑒𝑥𝑝, respectively) could thus be inferred 
by curve fitting to the measured fluorescence recovery curves. 
Assuming first order kinetics for both import and export: 
 
𝑑𝐶𝑛𝑢𝑐
𝑑𝑡
 = 𝑘𝑖𝑚𝑝 ∙  𝐶𝑐𝑦𝑡 −  𝑘𝑒𝑥𝑝 ∙  𝐶𝑛𝑢𝑐 (8) 
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where  𝐶𝑐𝑦𝑡  and 𝐶𝑛𝑢𝑐  denote the concentrations of nuclear and cytoplasmic 
Smad2, respectively; 𝑘𝑖𝑚𝑝 and 𝑘𝑒𝑥𝑝 are Smad2 nuclear import and export rates, 
respectively. 
During the fluorescence recovery process, the total amount of fluorescence 
does not change, which is equal to the total amount of cytoplasmic fluorescence 
immediately after photobleaching (assuming a complete photobeaching, i.e.,  
𝐶𝑛𝑢𝑐 (𝑡 = 0)  = 0). Thus there is the mass conservation: 
 𝐶𝑐𝑦𝑡0 = 𝐶𝑐𝑦𝑡 +  𝐶𝑛𝑢𝑐 𝑅⁄  (9) 
where 𝐶𝑐𝑦𝑡0 denotes 𝐶𝑐𝑦𝑡 (𝑡 = 0), i.e., the initial concentration of cytoplasmic 
fluorescent signal immediately after photobleaching; 𝑅  denotes the accessible 
cytoplasmic-to-nuclear volume ratio calculated in section 5.3.1.5. 
The change of nuclear fluorescence, i.e., the ODE (8) could then be solved 
analytically as follows239:  
 𝐶𝑛𝑢𝑐(t) = 𝐶𝑐𝑦𝑡0 ∙
𝑅 ∙ 𝑘𝑖𝑚𝑝(1 − e
−(𝑅∙𝑘𝑒𝑥𝑝+𝑘𝑖𝑚𝑝)∙t)
𝑅 ∙ 𝑘𝑒𝑥𝑝 + 𝑘𝑖𝑚𝑝
 (10) 
At steady state, i.e., 𝑡 → ∞,  
 𝐶𝑛𝑢𝑐𝑠𝑡𝑒𝑎𝑑𝑦 = 𝐶𝑐𝑦𝑡0 ∙  
𝑅 ∙ 𝑘𝑖𝑚𝑝
𝑅 ∙ 𝑘𝑒𝑥𝑝 + 𝑘𝑖𝑚𝑝
 (11) 
Therefore, the function (10) could be rewritten as: 
 𝐶𝑛𝑢𝑐(t) = 𝐶𝑛𝑢𝑐𝑠𝑡𝑒𝑎𝑑𝑦 ∙ (1 − e
−(𝑅∙𝑘𝑒𝑥𝑝+𝑘𝑖𝑚𝑝)∙t) (12) 
By fitting the data of nuclear FRAP curve to (12),  (𝑅 ∙ 𝑘𝑒𝑥𝑝 + 𝑘𝑖𝑚𝑝) could be 
obtained. Then combining with equation (11), both  𝑘𝑖𝑚𝑝  and 𝑘𝑒𝑥𝑝  could be 
derived. 
To implement, briefly, unstimulated live optoHela cells were photobleached in 
the whole nuclear region, the reappearance of iRFP signal was monitored at a 
frequency of 2s-per-image (Figure 5.3.4 A), until a steady state was reached. 
Dynamics of the nuclear iRFP signal in multiple cells were quantified and fitted 
to the exponential function (12) using the Curve Fitting Toolbox in MATLAB 
(Figure 5.3.4 B), the import and export rate parameters for iRFP-Smad2 could 
therefore be obtained (Figure 5.3.4 C).  
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Figure 5.3.4  Determination of the Smad2 translocation kinetics.  (A) 
Representative images of a photobleaching experiment. The channel for optoTβRII 
(yellow) was used for nucleus segmentation for photobleaching. Images of the iRFP-
Smad2 channel (red) were taken before and after photobleaching: t = 1 min before, t = 0 
sec, t = 30 sec, t = 60 sec and t = 300 sec after photobleaching. Scale bar= 10µm. (B) 
Quantification of nuclear iRFP intensity in multiple cells over time, normalized by the 
cytoplasmic fluorescence immediately after the bleach (open circles, n= 10, +/-SD). The 
solid black line represents the model fitting with the obtained values of 𝑘𝑖𝑚𝑝 (0.0051 s-1) 
and 𝑘𝑒𝑥𝑝 (0.0084 s -1), the black dashed line represents the corresponding cytoplasmic 
iRFP signal dynamics. (C) Boxplots of the characteristic parameters. 
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In addition, the steady state of the cytoplasmic concentration could also be 
derived: 
 𝐶𝑐𝑦𝑡𝑠𝑡𝑒𝑎𝑑𝑦 = 𝐶𝑐𝑦𝑡0 ∙  
𝑅 ∙ 𝑘𝑒𝑥𝑝
𝑅 ∙ 𝑘𝑒𝑥𝑝 + 𝑘𝑖𝑚𝑝
 (13) 
 
The Smad2 N2C ratio at steady state could be derived by combing (11) and 
(13): 
 
𝐶𝑛𝑢𝑐𝑠𝑡𝑒𝑎𝑑𝑦
𝐶𝑐𝑦𝑡𝑠𝑡𝑒𝑎𝑑𝑦
=
𝑘𝑖𝑚𝑝
𝑘𝑒𝑥𝑝
 (14) 
 
The total amount of iRFP-Smad2 is already known to be 260.05 nM (Table 
5.3-1), which could be calculated by: 
 
𝐶𝑛𝑢𝑐𝑠𝑡𝑒𝑎𝑑𝑦 ∙ 1 + 𝐶𝑐𝑦𝑡𝑠𝑡𝑒𝑎𝑑𝑦 ∙ 𝑅 
1 + 𝑅
=   𝐶𝑡𝑜𝑡𝑎𝑙 (15) 
 
Combing equations (14) and (15), the initial steady state concentrations of both 
nuclear and cytoplasmic Smad2 could be calculated. The detailed values are 
shown in Table 5.3-3. 
Concerning the endogenous Smad4 in Hela cells, immunofluorescence 
experiments showed that the steady-state N2C ratio of Smad4 before 
perturbation in Hela cells is around 3.22, which equals the ratio of its nuclear 
import to export rate, as indicated by equation (14). As the Smad4 nuclear import 
occurs with comparable rate to that of Smad2133, we used the same import rate of 
Smad2 for Smad4. The nuclear export rate of Smad4 could therefore be deduced. 
By knowing the total amount of Smad4 to be 98.64 nM (Table 5.3-1), the initial 
steady state concentrations of both nuclear and cytoplasmic Smad4 could then be 
calculated by combing equations (14) and (15). The detailed values are shown in 
Table 5.3-3. 
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Table 5.3-2 Summary of the derived parameter values based on 
experimental data or published models 
Parameter Value * Annotation Reference 
Receptor Module 
𝑉𝑚𝑎𝑥 5 sec-1 maximum rate of optoTβRI activation this work 
𝐾𝑀 0.1 
light intensity at which the reaction rate 
is half of the 𝑉𝑚𝑎𝑥 
this work 
𝑘𝑜𝑛
𝑜𝑝𝑡𝑜𝑇𝑅𝑠
 0.144 nM-1min-1 optoTβRs association rate constant this work 
𝑘𝑑𝑖𝑠𝑠
𝑜𝑝𝑡𝑜𝑇𝑅𝑠
 0.1 min-1 optoTβRs dissociation rate constant this work 
Smad Module 
𝑘𝑖𝑚𝑝
𝑆2  0.306 min-1 Smad2 nuclear import rate constant this work 
𝑘𝑒𝑥𝑝
𝑆2  1.34 min-1 Smad2 nuclear export rate constant this work 
𝑘𝑖𝑚𝑝
𝑆4  0.306 min-1 Smad4 nuclear import rate constant 
this work , 
240,241 
𝑘𝑒𝑥𝑝
𝑆4  0.253 min-1 Smad4 nuclear export rate constant this work 
𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 1 min-1 
Smad complexes dissociation rate 
constant 
240 
Compartment parameters 
𝑉𝑐𝑦𝑡 2.66 pl 
Volume of the cytoplasmic 
compartment 
this work, 
235 
𝑉𝑛𝑢𝑐 1 pl Volume of the nuclear compartment 
this work, 
235 
* The parameters were rounded to 3 significant digits. 
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Table 5.3-3  Summary of model initial conditions 
Species Value a) Annotation Compartment 
Receptor Module  
Light 1 light intensity Cytoplasm 
optoT1R 39.46 nM optoTβRI Cytoplasm b) 
ioptoT1R 8.88 nM optoTβRII before light stimulation Cytoplasm 
optoT2R 0 nM 
activated optoTβRII upon light 
stimulation 
Cytoplasm 
optoRC 0 nM optoTβRs complex Cytoplasm b) 
Smad Module  
S2c 495.2 nM Smad2 Cytoplasm 
S2n 300.7 nM Smad2 Nucleus 
S4c 61.4 nM Smad4 Cytoplasm 
S4n 197.7 nM Smad4 Nucleus 
pS2c 0 nM phosphorylated Smad2 monomer Cytoplasm 
pS2n 0 nM phosphorylated Smad2 monomer Nucleus 
pS2S2c 0 nM phosphorylated Smad2 dimer  Cytoplasm 
pS2S2n 0 nM phosphorylated Smad2 dimer  Nucleus 
pS2S4c 0 nM phosphorylated Smad2-Smad4 complex Cytoplasm 
pS2S4n 0 nM phosphorylated Smad2-Smad4 complex Nucleus 
a) The initial concentration values were rounded to 3 effective digits.  
b) Its actual localization is the plasma membrane, but still could be considered to be the 
cytoplasm for simplification.  
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While the above-mentioned parameter values could be measured by 
experiments, other parameters are more difficult to access directly, including the 
following parameters: 
− 𝑘𝑝ℎ𝑜𝑠𝑆2  (nM-1min-1):  
Rate constant for iRFP-Smad2 phosphorylation by the activated 
receptor complex (optoRC); 
− 𝑘𝑑𝑒𝑝ℎ𝑜𝑠𝑆2  (min-1):  
Rate constant for iRFP-Smad2 dephosphorylation by phosphatase in 
the nucleus. Here we assumed a constant level of phosphatase and 
mass action kinetics, hence we omitted the concentration of 
phosphatase, and used a single parameter 𝑘𝑑𝑒𝑝ℎ𝑜𝑠
𝑆2 to represent the rate 
for iRFP-Smad2 dephosphorylation; 
− 𝑘𝑜𝑛𝑆𝑚𝑎𝑑𝑠 (nM-1min-1):  
The rate constant for Smads complex dissociation ( 𝑘𝑑𝑖𝑠𝑠
𝑆𝑚𝑎𝑑𝑠 ) 
characterizes the Smad complex stability, and is the ratio of two kinetic 
rates: 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠 over 𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠
. Here we used the same estimated off-rate 
of 1 min-1 as in Schmierer’s paper133, which corresponds to an averaged 
complex life time of approximate 1 min. Sensitivity analysis showed 
that 𝑘𝑜𝑓𝑓
𝑆𝑚𝑎𝑑𝑠  does not significantly influence system behavior. The 
corresponding 𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠  was optimized and the dissociation rate 
constant could be calculated. 
− 𝑘𝑖𝑚𝑝𝑆𝑚𝑎𝑑𝑠 (min-1):  
Rate constant for Smads complex nuclear import. 
These parameters were optimized by simultaneously fitting several 
experimental data sets. The optimal set of parameters was then used for the 
subsequent simulations. To do this, we used a parallel parameter estimation 
tool242, which applied the algorithm of stochastic ranking evolution strategy 
(SRES)243. Three datasets generated under different stimulation conditions were 
used for the estimation: 
− Time course of Smad2 N2C ratio in response to frequent light stimulation 
(1 pulse every 10 minutes); 
− Time course of Smad2 N2C ratio to in response to a single pulse of light 
stimulation; 
− Time course of Smad2 N2C ratio in response to pulsed light stimulations at 
a low frequency (1 pulse every 180 minutes). 
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Due to the noise inherent in biological systems as well as in experimental 
measurements, the best-fit values might not be the only set of parameters that 
could fit within the error-bars of the experimental data. Certain deviation of the 
parameters from their best-fit values will still produce reasonable fits. However, 
due to the different properties of different parameters, the confidence intervals of 
these parameters could vary a lot. Here we implemented statistical analysis for 
the best-fit parameters. For calculating their 95% confidence intervals, we utilized 
a profile likelihood exploit algorithm244. In the meantime, we also tried to 
generate a series (5000 sets) of new synthetic data sets from the experimental data 
sets by the bootstrap method245, and independently performed parameter 
estimations to obtain 5000 best fit parameter sets, which was followed by 
calculating their distributions as well as standard deviations. Both of these two 
statistical analyses were implemented in a parallel parameter estimation tool 
SBML-PET-MPI242. Results were shown in Table 5.3-4. 
 
Table 5.3-4 Statistical analysis of the estimated parameters 
Parameter (Unit) Best fit a) 
95% confidence 
interval b) 
Mean ± SD c) 
Bounds in 
parameter 
estimation 
𝑘𝑝ℎ𝑜𝑠
𝑆2  (nM-1min-1) 0.005936 (0.005639; 
0.006530) 
0.00616 ± 
0.000679 
0.001 ~ 1000 
𝑘𝑑𝑒𝑝ℎ𝑜𝑠
𝑆2  (min-1) 1.668 (1.335;2.002) 2.37 ± 2.43 0.001 ~ 1000 
𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠 (nM-1min-1) 2.300 (2.285; 2.303) 5.36 ± 13.5 0.001 ~ 1000 
𝑘𝑖𝑚𝑝
𝑆𝑚𝑎𝑑𝑠 (min-1) 0.4549 (0.3639; 0.4563) 0.607  ± 0.621 0.001 ~ 1000 
a) The estimated parameters were rounded to 4 significant digits.  
b) The 95% confidence intervals derived from profile likelihood analysis.  
c) The mean and 1 standard deviation calculated from 5000 optimizations from synthetic data 
sets by the bootstrap method. 
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We calculated the correlation coefficients (Spearsman’s rho) among the four 
estimated parameter by using the above obtained 5000 best fit parameter sets. We 
also plotted the four estimated parameters against each other for visualization 
(Figure 5.3.5). Correlation between 𝑘𝑑𝑒𝑝ℎ𝑜𝑠
𝑆2  and 𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠  was observed, this 
could explain the less constrained results of the above statistical analysis on them 
(Table 5.3-4). 
 
Figure 5.3.5  Parameter Correlation Analysis.  The estimated parameters 
were plotted against each other by using the 5000 sets of best fit parameters obtained 
during the statistical analysis (section 5.3.3). Correlation between 𝑘𝑜𝑛
𝑆𝑚𝑎𝑑𝑠  and 𝑘𝑑𝑒𝑝ℎ𝑜𝑠
𝑆2   
was observed.  
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Parameter sensitivity analysis is a measure for the magnitude of the effect on 
the system output by changing a specific parameter. For parameter sensitivity 
analysis, each parameter was varied and the corresponding change of the output 
was evaluated. Here we defined the maximal nuclear-to-cytoplasmic iRFP-Smad2 
signal as the output. Therefore the scaled sensitivity coefficients are calculated as 
the following: 
 𝑠𝑝𝑖 =
𝜕(𝑆𝑚𝑎𝑑2_𝑁2𝐶)
𝑆𝑚𝑎𝑑2_𝑁2𝐶
𝜕𝑝𝑖
𝑝𝑖
   (16) 
where 𝑆𝑚𝑎𝑑2_𝑁2𝐶  is the maximal nuclear-to-cytoplasmic iRFP-Smad2 in 
response to a pulsed light stimulation; 𝑝𝑖 denotes each individual parameters.  
As shown in Figure 5.3.6, Smad2 signaling (N2C ratio of Smad2) is sensitive to 
the changes of  𝑘𝑖𝑚𝑝
𝑆2  , 𝑘𝑒𝑥𝑝
𝑆2  , 𝑘𝑝ℎ𝑜𝑠
𝑆2  and 𝑘𝑑𝑖𝑠𝑠
𝑜𝑝𝑡𝑜𝑇𝑅𝑠, while it is relatively robust against 
changes  of other parameters, especially, 𝑘𝑖𝑚𝑝
𝑆4  , 𝑘𝑒𝑥𝑝
𝑆4  , 𝑘𝑜𝑛
𝑜𝑝𝑡𝑜𝑇𝑅𝑠 and 𝐾𝑀. 
 
Figure 5.3.6  Sensitivity analysis of the parameters on Smad2 signaling 
response. Scaled sensitivity coefficients for the maximal N2C iRFP-Smad2 signal to 
variations of individual parameters.  
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To assess how good could the model fit the experimental data sets used in the 
procedure of parameter estimation, we checked whether model simulations 
could reproduce those data sets. Simulation results showed that the simulations 
were within the error bars for all the three different experimental conditions, 
indicating a good agreement between the model simulations and the 
experimental data that were used in parameter estimation (Figure 5.4.1). 
 
Figure 5.4.1  Comparisons of simulation results and the experimental 
data that were used for parameter estimation.  Red circles with error bars denote 
the quantitative experimental data; the companioning grey curves denote the 
corresponding model predictions with the optimized parameters. Both the experimental 
data and model predictions were scaled by the maximum value in the respective data set. 
(A) Results of a frequent pulsed stimulation (1 pulse every 10 minutes). (B) Results of a 
single pulsed stimulation. (C) Results of a less frequent pulsed stimulation (1 pulse every 
180 minutes). (D) Parameter optimization history.  
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To do model validation, we tested whether the model could also accurately 
predict Smad2 responses upon alternative stimulation patterns. We did new live-
cell imaging experiments in which cells were stimulated by a short pulse of blue 
light in every one hour, or every two hours. Both the two experimental results 
agreed well with the corresponding model simulation results (Figure 5.4.2). 
Therefore, the model could successfully predict iRFP-Smad2 signaling behaviors 
of the optoTGFβ system upon various patterns of light stimulation. 
 
Figure 5.4.2  Comparisons of simulation results and the experimental 
data that were not used for parameter estimation.  Red circles with error bars 
denote the experimental data; the companioning grey curves denote the corresponding 
model predictions. Both the experimental data and model predictions were normalized 
by the maximal value in the respective data set. (A) Results of experiments in which cells 
were stimulated by one pulse per hour. (B) Results of experiments in which cells were 
stimulated by one pulse per two hours. 
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Continuous or frequent blue light irradiation would induce Smad2 activation 
that could be sustained for eight hours (Figure 3.5.1 B & D). This indicates the 
absence of efficient negative feedback controls during this time range. In addition, 
below a certain intensity threshold, blue light with a higher intensity could 
induce a higher level of Smad2 phosphorylation (Figure 3.5.2). This suggests that 
an input with higher energy could trigger a stronger Smad2 response, as long as 
the input is within the unsaturation range. Since a higher frequency of pulsed 
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light stimulation means higher light energy being inputted during a defined time 
range (each single pulse has the same defined amount of energy), therefore, the 
higher frequency of pulsed light we implement, the higher level of Smad2 
signaling we should observe. 
To test if light stimulation with a higher frequency induces a stronger Smad2 
response, we simulated Smad2 activities in response to various frequencies of 
pulsed light stimulation. To quantify the Smad2 response, we calculated both the 
amount of phosphorylated Smad2 (Figure 5.4.3 A & B), and the N2C ratio of 
Smad2 (Figure 5.4.3 C & D). As expected, below a threshold of ~10-2 Hz, higher 
frequency indeed triggered stronger Smad2 response, no matter in terms of the 
maximum level, or in terms of the cumulative level (the total accumulated signal, 
i.e., the area under the curve of signal dynamics). 
 
Figure 5.4.3  Frequency responses of the optoTGFβ system. The Smad2 
activation responses were plotted versus pulsed light input frequencies. The responses 
were measured in terms of the maximum level of phosphorylated Smad2 (A), or the 
cumulative level of phosphorylated Smad2 during the first eight hours of stimulation 
(B), or the maximum level of Smad2 N2C ratio (C), or the cumulative level of Smad2 
N2C ratio during the first eight hours of stimulation (D). 
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To explore the correlation between the signaling activity and the abundance of 
the involved proteins, we did parameter scan for the abundance of the four 
proteins: optoTβRII, optoTβRI, Smad2 and Smad4. For each protein, we set the 
scanning range to be between half of its measured concentration (minimum) and 
two-fold of its measured concentration (maximum).  
First we ran simulations for single pulsed stimulation experiments, and used 
the time course of Smad2 N2C ratio as the readout of TGFβ signaling activity. 
Simulation results showed that the signaling activity varied a lot when scanning 
the abundance of optoTβRII (Figure 5.4.4 A), but nearly stayed at the same level 
when varying the abundance of optoTβRI (Figure 5.4.4 B). Similar results were 
observed for continuous stimulation experiments (Figure 5.4.4 E-F). 
The fact that the results of varying each of the two receptors are poles apart 
might arise from the inconsistent expression levels of the two chimeric receptors. 
Due to the longer sequence and thus larger conformation of the PHR domain in 
the optoTβRII construct, the expression level of optoTβRII is much lower than 
that of optoTβRI. Therefore, the pool of optoTβRI is always saturate with respect 
to the optoTβRII proteins. Varying the amount of optoTβRI in a certain range 
does not affect the signaling a lot, as long as it is in the range of saturation. In fact, 
concerning the protein expression levels in the optoHela cells in this study, 
optoTβRII is only ¼ of optoTβRI (Table 5.3-1). Therefore, the smallest value in 
the scanning range for optoTβRI abundance is larger than all the scanned values 
for the abundance of optoTβRII. Varying the optoTβRI abundance within this 
saturation range would certainly have little impact on the signaling. In contrast, 
the amount of optoTβRII is essential for determining the strength of signaling.  
Interestingly, while increasing the abundance of either Smad2 or Smad4 could 
lift the signaling activation level under continuous stimulation conditions (Figure 
5.4.4 G-H), in the experiments of single pulsed stimulation, it lowered the 
signaling activity when raising the Smad2 abundance within a certain range 
(Figure 5.4.4 C). This might be the consequence of adopting the N2C ratio of 
Smad2 as the readout. Upon the same intensity of light stimulation, (and within a 
certain range of Smad2 abundance,) less amount of Smad2 leads to less Smad2 
remaining in the cytoplasmic compartment following signaling activation (i.e. 
higher depletion percentage of the cytoplasmic Smad2), which results in larger 
N2C ratio. In the continuous stimulation experiments, more and more 
cytoplasmic Smad2 could enter the nucleus before reaching a steady state, at 
which the N2C ratio is higher in the cells containing more Smad2. However, the 
total amount of phosphorylated Smad2 should not decrease when raising the 
Smad2 abundance under both stimulation conditions, which was confirmed by 
the same parameter scanning simulations. 
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Figure 5.4.4 Results of parameter scanning for protein abundances. (A-
D) Results for single pulsed stimulation; (E-H) Results for continuous stimulation. 
Curves represent the dynamics of Smad2 N2C ratio. The color of the curves codes the 
varied protein (blue, green, red or yellow denote varying the abundance of optoTβRII, 
optoTβRI, Smad2 or Smad4, respectively). The darker the color is, the more abundant the 
respective protein is. The black curves represent the simulation result without varying 
parameters.  
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In this chapter, we built a mathematical model on the chimeric optoTGFβ 
system by combining the two modules: the light-sensitive protein pair for 
controlling the activities of the receptors (optoTβRs), and the downstream Smad2 
signaling network. This model is composed of 15 species, 17 reactions and 13 
kinetic parameters (Table 5.3-3, Table 5.2-1 and Table 5.3-2 & Table 5.3-4, 
respectively). The initial concentrations of the involved proteins were inferred by 
comparing to that of their endogenous counterparts, which were in turn 
determined by referring to the public databases. Among the 13 kinetic 
parameters, 9 of them were determined by experiments or based on justifiable 
assumptions; the remaining 4 parameters were optimized by data fitting. The 
calibrated model could not only reproduce the data sets used for parameter 
estimation, but also predict dynamic behaviors of Smad2 under new stimulation 
conditions.  By using the characterized properties (i.e. the kinetic parameter 
values) of the Smad2 signaling module, with additional data of signaling 
activation upon TGFβ ligand stimulation, it is possible to further infer the 
dynamic properties of the endogenous receptor module (e.g., ligand binding, 
receptor internalization and recycling, etc.) in the Hela cells. 
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In addition to the discussions following the above detailed results, here, I 
would like to make some general discussions regarding the entire project from 
the following perspectives: (1) We compared the optogenetic approach used in 
this project with other experimental approaches that are used for manipulating 
TGFβ signaling. We concluded that it is complementary to other approaches, and 
provides additional control of TGFβ signaling. (2) Combining with mathematical 
modeling, we found that optoTβRs are not internalized when activating TGFβ 
signaling in response to blue light irradiation, which suggests that endocytosis of 
TGFβ receptors is not necessary for Smad signaling. (3) We further discussed 
other explanations for the observations that light could induce faster and 
stronger TGFβ signaling. (4) We also discussed the higher precision of light 
stimulation, i.e., stimulation at the subcellular level. (5) We then talked about one 
of the primary advantages of the optoTGFβ system, isolating the signaling 
circuits specifically conducted by the two receptors (i.e., TβRI and TβRII), which 
facilitates better interrogation and control of TGFβ signaling. (6) We also 
discussed possible improvements and potential applications of the optoTGFβ 
system. 
 
 
 6 
 General Discussion and Future Perspectives 
  
94 
 β β
Although traditional chemical and genetic approaches (e.g., small molecule 
inhibition, RNA silencing, genetic knockdown/knockout perturbations) have 
helped us manipulate TGFβ signaling, or identify the functions of key molecular 
mechanisms in regulating TGFβ signaling, these tools have common limitations. 
For instance, there might be potential off-target effects on cellular responses; it 
might be difficult to remove the chemicals, or reverse their effects when 
necessary; it is hard to control TGFβ signaling with high spatial precision by 
these approaches. Moreover, it has been shown that TGFβ ligands are 
internalized and degraded by the responsive cells246,247. The ligand depletion 
makes it difficult to control the dose of TGFβ ligand in the medium over time. 
The optoTGFβ system shows great advantages to overcome these problems, due 
to the technical specificities of the optical control. Compared with the traditional 
chemical treatment, the optoTGFβ system enables precise stimulation in 
thousands of patterns. More importantly, the optoTGFβ system can be used to 
control TGFβ signaling dynamics with high spatiotemporal precision at the 
single cell level, while it is hard to apply the classical biological tools to 
manipulate cell behaviors at the single cell resolution.   
Another powerful and competing tool for precise signaling perturbation is the 
microfluidics technology. However, although temporal perturbation could be 
achieved conveniently in most contexts, precise spatial stimulation is still difficult 
to be implemented in the microfluidic systems. Presently, it only allows 
generating limited types of chemical gradient in the microfluidic channels, rather 
than implementing various patterns of spatially restricted stimulation. Besides, 
even for the temporal control, it is hard to implement sharp transitions of 
stimulation. When flushing the channels at high speed to implement a sudden 
change of input, unwanted responses might be induced, this could interfere with 
the experimental results. Furthermore, it is usually very expensive to build up a 
microfluidic system, or purchase commercially available equipment or devices, 
as it heavily relies on the advanced technologies of manufacturing 
microminiaturized devices. In contrast, with the advantageous properties of the 
light controllable optoTGFβ system, it is possible to apply any types of 
temporally and spatially restricted perturbations. 
Therefore, although the optoTGFβ system could not completely replace the 
role of the endogenous TGFβ signaling machinery, it is complementary to other 
tools, and provides additional control of TGFβ signaling activity by facilitating 
various perturbations in time and space. 
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Instead of using the entire proteins of the endogenous TGFβ receptors, we 
only employed the cytoplasmic region of them to construct optoTβRs. This is 
consistent with the previous studies (Figure 2.1.1), and again confirms that 
neither the extracellular domain nor the transmembrane region of TβRs is 
indispensable for TGFβ signaling activation. As long as their cytoplasmic 
domains could be brought close enough to facilitate phosphorylation of TβRI by 
the constitutively activated TβRII, TGFβ signaling could be initiated. However, 
from the evolutional perspective, the extracellular domain is a rational design of 
the nature. For better adaptation and evolvement, cells need to communicate 
with each other or with their environment now and then, by responding to the 
numerous and specific types of cues. On the other hand, as an evolution product, 
plasma membrane functions as a protective wall surrounding all the machinery 
of a cell against the complex extracellular environment, and is only selectively 
permeable to the necessary materials for its survival. Not everything could enter 
the living cells easily. Even for the molecules that could really enter the cells, not 
all of them are transported through the same biophysical mechanism. TGFβ is a 
small protein, but much larger than small chemicals such as carbon dioxide (CO2), 
ion, and even sugars or amino acids. Therefore, it can neither pass the plasma 
membrane freely by passive osmosis or diffusion, nor enter the cells by 
transmembrane proteins channels or transporters easily. Producing membrane 
receptors with extracellular domains specific to the TGFβ ligand structure is the 
most convenient and rational way to sense the TGFβ signal.  
Upon ligand activation, the ligand-receptors complex (LRC) is internalized, 
which on the one hand facilitates signaling via the clathrin-dependent manner, 
on the other hand removes the signal via the lipid-raft-dependent manner 
(Figure 1.2.7). Penheiter et al. have shown that the internalization of LRC is 
necessary for Smad2/Smad3 activation and downstream signaling. However, this 
conclusion was based on the study of blocking internalization by low 
temperature treatment. The absence of Smads activation might result from a low 
temperature-dependent response, rather than a direct effect of non-endocytosis248. 
On the contrary, another study by depleting intracellular potassium or 
expressing a mutant dynamin suggested that receptor internalization is 
dispensable for TGFβ induced Smad2 activation249. The contrast between these 
two conclusions might arise from the differences between the specific cell lines 
they investigated on. Nonetheless, it didn’t rule out the necessity of signaling 
taking place on the plasma membrane. 
In the endogenous TGFβ signaling pathway, the plasma membrane 
participates in the signaling by engulfing LRC. How about in the optoTGFβ 
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system? As the Myr sequence was inserted randomly to the plasma membrane, it 
is not likely that light could trigger specific endocytosis of the activated receptors. 
Although it is difficult to interrogate if the activated optoTβRs undergo 
endocytosis upon light activation, we could examine it easily by mathematical 
modeling (Figure 6.2.1 A). In theory, under sparse pulsed stimulation conditions, 
it is difficult to distinguish whether internalization happens or not, as optoTβRII 
always returns from the plasma membrane following a pulsed stimulation, no 
matter it is internalized or not. However, under frequent stimulation conditions, 
if endocytosis exists, a certain portion of optoTβRI will be internalized and thus 
stay in the cytoplasm. Therefore the depletion of cytoplasmic optoTβRII upon the 
next light stimulation should decrease, which means there always exists a certain 
portion of optoTβRII in the cytoplasm throughout the experiment. On the 
contrary, if the activated optoRCs do not undergo endocytosis, all optoTβRI 
should stay on the plasma membrane, and the depletion of optoTβRII following 
each light pulse will always be complete. Therefore, we could easily distinguish 
whether internalization exists or not by frequent stimulation experiments. 
To test this “thought experiment” by model simulation, we included the 
endocytosis processes in the model (Figure 6.2.1 A), and performed parameter 
estimation as before (Figure 6.2.1 B). The new model fit the data well. We next 
ran a simulation for a frequent stimulation experiment (one pulse in every 10 
minutes), and found that indeed the bulk of optoTβRII kept staying in the 
cytoplasm after several minutes. Although the amount of cytoplasmic optoTβRII 
(including the inactivated optoTβRII, activated optoTβRII, and endocytosed 
optoTβRs complex) fluctuated in accordance with light stimulation, as time goes 
on, less and less optoTβRII would translocate onto the plasma membrane 
following each stimulation. Finally, from the 4th hour on, a plateau was reached 
where almost all optoTβRII kept staying in the cytoplasm (Figure 6.2.1 C). 
According to this model prediction, we should observe a sharp decline of 
cytoplasmic optoTβRII to the lowest level after the first stimulation, and at least 
half of the total optoTβRII remaining in the cytoplasm from the second 
stimulation onwards.  
However, it was not the case in reality. When we quantified cytoplasmic 
optoTβRII signal in the experiments with the same stimulation condition, it 
declined upon the first stimulation, but continued to decrease upon the following 
stimulations (Figure 6.2.1 D). We also ran a simulation by assuming that 
internalization isn’t involved in the optoTGFβ signaling, the localization of 
optoTβRII was consistent with the experimental observations (Figure 6.2.1 D, 
grey curve).  These results imply that the activated optoRCs do not undergo 
endocytosis upon activation. This suggests that endocytosis of TGFβ receptors is 
dispensable for Smad2 activation, which is consistent with the previous finding 
that Smad2 could still be activated in the absence of receptor internalization249.  
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Figure 6.2.1  optoTβRs do not undergo endocytosis when activated.    
(A) Scheme of an optoTGFβ model involving receptor endocytosis processes. (B) Values 
of the estimated parameters. (C) Dynamics of different species containing optoTβRII 
upon frequent stimulation in model simulation. (D) Inconsistency between simulation 
(black curve) and image quantification (red circles). For comparison, simulation result 
based on the model (Figure 5.1.1) without endocytosis was also shown (grey curve). 
Note that compared with model simulations, experiments couldn’t capture data 
continuously, therefore, only a few discrete data points were shown in the figure. 
optoHela cells were stimulated by one pulse of blue light in every 10 minutes, 
cytoplasmic optoTβRII signal (immediately after each pulsed stimulation) was 
quantified and compared with model predictions. Data were scaled between 0 and 1. ki, 
receptor internalization rate; kr, receptor recycling rate. 
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Experimental verification could be done by directly monitoring the 
localization dynamics of fluorescence-labeled optoTβRII or optoTβRI following 
light stimulations in a TIRFM (total internal reflection fluorescent microscopy), or 
by checking if optoTβRII has the same localization with endosome marker 
proteins such as the small GTPase Rab1199,104 , clathrin adaptor protein DAB2105 or 
subunits of the clathrin-associated adaptor complex AP291. Furthermore, as 
optoTβRI is hung on the inner side of the plasma membrane, and the activation 
of the optoTGFβ system is through the translocation of cytoplasmic optoTβRII to 
the plasma membrane, we still cannot exclude the necessity of the plasma 
membrane for activating the TGFβ type I receptor. 
 
 β
Compared with TGFβ ligand stimulation, blue light stimulation could induce 
faster and stronger iRFP-Smad2 signaling (Section 4.3.2). One of the possible 
explanations might be the faster kinetics of receptor interaction and activation in 
the optoTGFβ system. It might also result from the amount of the receptors that 
actually mediate the signaling. According to the previous studies on the 
endogenous TGFβ signaling pathway108,136, only around 10 percent of TβRI is on 
the cell surface. This plasma membrane localized portion of TβRI is the functional 
pool, which directly perceives TGFβ ligands and participates in the TGFβ 
signaling activation. In this surface pool of TβRI, only around 40 percent is 
activated in the first hour, even in response to a saturating dose of TGFβ 
stimulation136. However, in the optoTGFβ system, almost the entire ensemble of 
the chimeric receptor pool could be activated upon light activation, resulting in a 
higher saturation level of receptor activation. This indicates that, we could 
possibly expand the response regime and functionality of TGFβ signaling with 
the optoTGFβ system. 
There are also possibilities that optoTβRII also phosphorylates and activates 
the endogenous TβRI following light activation, which further increases the level 
of activated type I receptors. However, the possibility is very low. On the one 
hand, a typical Hela cell has a diameter of 20 microns235, corresponding to a 
surface area of over 1000 um2; a ~70 kDa size optoTβRI is a protein whose 
diameter is less than 6 nanometer250, and an endogenous TβRI is ~50kDa thus 
even smaller. Therefore the size of TβRI or optoTβRI is very small relative to the 
entire plasma membrane. On the other hand, the estimated protein expression 
level of the endogenous TβRI in a Hela cell is around 16 ppm (parts per million) 
237,251, which is higher than the optoTβRI expression level according to the western 
blotting experiment in our study (Figure 2.4.3). By assuming these proteins are 
evenly distributed on the plasma membrane, and knowing the total number of 
proteins in a Hela cell is ~ 10^10238, we could estimate the numbers of optoTβRI 
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and the endogenous TβRI on the plasma membrane are around 86000 and 16000 
molecules, respectively. Considering the large area of the plasma membrane, and 
the small volume of these proteins, this calculation suggests that both optoTβRI 
and the endogenous TβRI locate sparsely on the plasma membrane. Therefore, an 
endogenous TβRI could be activated upon light stimulation only if it happens to 
reside close to one of the sparsely distributed optoTβRI, whose probability is 
very low. In addition, a previous study showed that integrin-rich focal adhesions 
organize TβRII around a segregated pool of TβRI, and immobilize TβRI at these 
sites252. This further implies that TβRI is very unlikely to stay close to optoTβRI. 
Therefore, although it might occasionally happen that a light-activated optoTβRII 
phosphorylates an endogenous TβRI, the possibility would be very little. 
Light could induce stronger Smad2 activation, which is the upstream step of 
the TGFβ signaling pathway. It is highly possible that the downstream TGFβ 
responses are also affected, including the various targeted transcriptional 
activities, and the non-canonical TGFβ signaling circuits. By lifting the maximal 
level of upstream receptor activation as well as facilitating the stimulation input 
control, various cellular responses could be modulated easily with the optoTGFβ 
system, and even novel responses could possibly be developed. 
 
 
When demonstrating the spatiotemporal control of the optoTGFβ system 
(Figure 4.1.1), although we irradiated cells only at a specific small region within 
the cell (yellow circles), Smad2 translocated into the nucleus evenly from every 
direction. This might be due to the imprecision of stimulation, or the rapid 
diffusion of activated Smad2 throughout the cytoplasm. The imprecision of 
stimulation might be in turn due to the technical limitation of the laser source, or 
the inherent scattering of light by the materials it passes through (such as air, 
plastic, cell culture medium or cell biomass). Thus the entire collection of 
optoTβRII in the cell was activated simultaneously. Although this imprecision is 
trivial in most studies, it is still important to improve it for generalizing the 
application of the optoTGFβ system to a wider range of studies. 
The stimulation precision at the subcellular resolution is essential in some 
contexts, such as studies on cell polarity. Studies on polarized epithelial cells 
have revealed that the TGFβ receptors are exclusively basolateral at high cell 
density, which prevents Smad signaling by apical TGFβ 253,254. Loss of polarity 
was observed during early carcinogenesis, which may lead to TGFβ mediated 
EMT255,256 and cancer cell dissemination257,258. However, the detailed molecular 
mechanism is still not clear. It was quite difficult to precisely control polarized 
signaling activation and to untangle the role of polarity in carcinogenesis. Now 
the optoTGFβ system sheds light on solving this problem. By improving the 
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stimulation precision, subcellular TGFβ signaling control could be realized, 
which could benefit the field of studies on cell polarity. 
In addition, single cell mathematical models have been developed to explore 
the spatial intercellular signaling. A lot of interesting characteristics were 
predicted on unbalanced signaling transduction in individual cells259-263. However, 
some direct evidences from biological experiments are still difficult to 
achieve.  Now the optogenetics shows great potential as a new yet powerful 
approach to validate those single cell model predictions. 
The desire for subcellular controllable tools raises the question of how to 
improve the precision of optical control. There are several ways, from the 
technical aspect to the manipulation perspective. On the one hand, technical 
imprecision is mainly caused by the transmission medium or light source. 
Therefore technical precision could be increased by methods such as replacing 
the plastic slices with glass ones264. Multi-photon excitation is an alternative 
option due to its more confined region of excitation at the focal plane, compared 
with single-photon excitation265. Finer spatial stimulation could also be realized 
by DMD (digital micro-mirror device), which is composed of an array of 
microscopic mirrors that can be toggled individually to project any pattern of 
light.  On the other hand, the input pattern of irradiation should be precisely 
controlled. For example, when precise and predictable control of optoTβRII is 
necessary, pulsed light stimulation is better than continuous illumination with 
comparable light energy215. There are several reasons. First of all, it limits 
unnecessary light irradiation on cells. If a short pulse is enough to activate all the 
light-sensitive proteins that present in the illumination volume, further 
illumination is redundant. Even if new inactivated light-sensitive proteins might 
diffuse into this illumination volume, most of the proteins in this illumination 
volume are already activated. Second, pulsed illumination avoids considering 
diffusion, which is hard to be predicted, and thus increases the predictability and 
reproducibility of the experiments. Third, pulsed illumination allows protein 
interactions to reset and be re-activated, which might improve the activation 
efficiency. For instance, in the optoTGFβ system, the reset of optoTβRII enables it 
to activate more optoTβRI upon the following pulsed stimulations. Usually, the 
ideal length and intensity of light stimulation are necessary to be optimized 
before experiments. It should be short but strong enough to activate all the light-
sensitive proteins in the illumination volume, but should avoid diffusion and 
replenishment with inactive proteins. 
By improving the stimulation precision, it is possible to apply the optoTGFβ 
system to manipulate TGFβ signaling at a specific subcellular region, which 
would benefit future studies at the subcellular level.   
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In this study, we focused on the TGFβ signaling specifically triggered by 
ligands of the TGFβ subfamily, which is only a branch of a large TGFβ 
superfamily. Although members of the TGFβ superfamily employ similar 
molecular mechanisms for signaling activation, each member has its unique 
binding affinities and activities, and thus implements distinct tasks in various cell 
types or different developmental stages. Examples of the TGFβ superfamily 
ligand are BMPs, Activin, Nodal, TGFβ, GDFs and AMH. To specifically perceive 
these ligands, there is a family of receptors, including various type I receptors 
and a series of type II receptors. Among them, the human genome encodes seven 
and five different type I and type II receptors, respectively. Despite the binding 
specificities of the ligands, some of the ligands could bind and activate multiple 
receptors (Figure 1.2.3). For example, besides binding to TβRI/TβRII to trigger 
the Smad2/Smad3 pathway, TGFβ ligands could also bind to ALK1/TβRII to 
activate the Smad1/Smad5/Smad8 pathway26,65,126. The employment of receptors 
in the TGFβ superfamily signaling can also overlap. TβRI could be interacted and 
activated by other type II receptors than TβRII, such as ActRIIB266,267. In the 
optoTGFβ system, the specific interaction between PHR and CIBN induces the 
specific binding between optoTβRI and optoTβRII, which originate from TβRI 
and TβRII, respectively. This avoids interference from signaling through other 
receptor pairs (e.g. ALK1/TβRII), which could also be induced by TGFβ ligands. 
Hence we could focus only on the TGFβ signaling transmitted through the 
TβRI/TβRII receptor pair. 
Besides, the endocytosis process involved in the endogenous TGFβ signaling 
further complicates the signaling pathway, which subjects the signaling to more 
delicate and elaborate regulations. However, this also makes it difficult to 
interrogate the properties of the pathway, especially when applying 
mathematical modeling methods on it. The optoTGFβ system simplifies the 
signaling process by excluding the endocytosis steps. Without endocytosis, 
which is subject to numerous regulations, TGFβ signaling in the optoTGFβ 
system could therefore be manipulated in a more predictable way. Mathematical 
models built on it are also easier to be calibrated. Moreover, it is also possible to 
compensate for the absent signaling regulations through precisely controlling the 
light stimulation pattern. 
Furthermore, when diving into the TGFβ ligand subfamily, there are mainly 3 
different isoforms of TGFβ: TGFβ1, TGFβ2 and TGFβ3. They differ in their 
coding gene’s sequences268,269, chromosomal localizations270-272, and their protein 
conformations, which lead to their differential biological activities32,273,274. Due to 
their unique physiological activities275, as well as their tissue-specific expression 
levels276, all the isoforms are indispensable in vivo, which was confirmed by the 
knock-out/null-mutation studies: TGFβ1 null mutation in mice could lead to 
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inflammatory diseases or early death277,278; TGFβ2 knock-out mice have 
distinctive developmental defects279; mice lacking TGFβ3 exhibit cleft palate 
which results from failures in secondary palate fusion280. In addition, gene 
replacement studies on the three isoforms showed partial rescue of the null-
mutant defective phenotypes281,282, which implies both their redundant and non-
overlapping functions. Nonetheless, they all signal through the same pair of 
receptors (TβRI/TβRII), which means that this pair of receptors could discern and 
transmit different information to downstream effectors via different activities of 
themselves. The conveniences of the optoTGFβ system could help to elucidate 
how exactly the receptors differentially mediate these signals, for example, 
through manipulating the dynamics of receptor activation to mimic the activities 
induced by the specific isoform, or to rescue the null-mutant phenotypes. 
Eventually, the same optoTGFβ system could be placed into specific tissues to 
implement unique functions by modulating light stimulation in vivo. 
Taken together, the optoTGFβ system dissects and isolates the two specific 
receptors from their isogenous counterparts, which could not only overcome the 
complexity of regulations on the ligand perceiving process (i.e., from ligands 
binding, until receptor activation), but also help to identify the differences among 
the signaling induced by different TGFβ isoforms. Endocytosis of activated 
receptors is also absent in the optoTGFβ system, which not only confirms the 
dispensability of it, but also facilitates investigation and mathematical modeling. 
In summary, these simplifications in the optoTGFβ system could help us better 
investigate the signaling pathway, and implement more predictable controls on it. 
 
 β
The current generation of the optoTGFβ system still has some limitations and 
could be further optimized for studying and manipulating the TGFβ signaling. 
For example, optoTβRI, optoTβRII and iRFP-Smad2 proteins are constitutively 
overexpressed with exogenous promoters. In the future, it would be useful to 
replace their endogenous counterparts with these chimeric proteins, thus express 
these proteins from their endogenous promoters by approaches such as the 
CRISPR/Cas9-mediated knock-in technology283,284. Such a version of the 
optoTGFβ system would be valuable for studying the TGFβ signaling under 
conditions more close to the physiological state. An alternative design is to 
control the expression of these chimeric proteins at different levels through using 
inducible gene expression systems. Furthermore, because of the multi-functional 
property of the TGFβ signaling, it would also be interesting to investigate the 
spatiotemporal control of downstream responses, by expressing reporters for 
specific TGFβ responsive genes, or markers of specific TGFβ dependent cellular 
responses. 
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Although the function of TGFβ signaling is versatile and context dependent, 
the signaling engine is essentially the same one. Therefore, the optoTGFβ system 
is potential for studying the TGFβ signaling at various levels. 
In the optoTGFβ system, iRFP-Smad2 is co-expressed to indicate the 
downstream Smad signaling in single cells. This property allows us to 
simultaneously monitor the dynamics of both receptor and Smad activation at 
the single cell level. This could help us establish quantitative relationships 
between the upstream TGFβ receptor activity and the downstream Smad 
signaling, which would facilitate quantitative modeling of the canonical TGFβ 
signaling pathway.  
In addition, benefited from its convenient way of stimulation implementation 
and data acquisition, the optoTGFβ system has great potential to help us 
investigate how cells respond to complex signals, such as repeated pulses of 
signal inputs, increasing input ramp or noisy signal inputs136,232,285. Mathematical 
models of the signaling pathway could then be developed or calibrated more 
precisely and efficiently. In such ways, the TGFβ signaling could be better 
characterized, and even new functions of TGFβ signaling might be revealed. 
Besides the canonical TGFβ signaling, quantitative studies on non-canonical 
signaling (Section 1.2.2) could also be facilitated by modulating light input and 
observing specific outputs with the optoTGFβ system. For instance, for cells 
undergoing EMT, in addition to the transcriptional effects of the canonical TβRI-
Smad pathway256,286, the activated TβRII directly phosphorylates PAR6, which 
recruits SMURF1 to induce RhoA degradation, followed by dissolution of tight 
junctions as well as polarized migration287,288. By expressing optoTβRs and 
additional signaling reporters in these epithelial cells, each of these steps could be 
conveniently and quantitatively studied. In the end, the processes of EMT might 
even be harnessed by simply modulating the light input. Crosstalks of TGFβ 
signaling with other signaling pathways such as MAPK289 and PI3K290,291 
pathways could also be interrogated, the biochemical links that might play 
crucial roles in some pathological processes292,293 could then be identified. 
Furthermore, the optoTGFβ system could be potentially generalized to other 
receptor-multimerization-dependent signaling pathways. Especially, the basic 
design of the optoTGFβ system can be adopted to build light controllable 
signaling systems for other branches of the TGFβ superfamily signaling. Some 
members of the TGFβ superfamily regulate important biological processes such 
as morphogen gradient formation and embryonic development. For these 
processes, it is essential to precisely control the temporal and spatial distribution 
of signaling activation. A recent study adapted the light-oxygen-voltage (LOV) 
optogenetic module to develop a photoactivatable Nodal receptor pair, Opto-
  
104 
acvr1b and Opto-acvr2b, for activating Nodal signaling220. In this Opto-acvr1b/2b 
system, both types of the Nodal receptors were expressed at the plasma 
membrane by injecting zebrafish embryos with their mRNAs. This Opto-
acvr1b/2b system was helpful and adequate to elucidate the pivotal role of Nodal 
signaling duration for cell fate specification at the population level. However, as 
the two types of receptors were not differentially labeled in this system, it is not 
convenient to monitor the expression level or the dynamics of the upstream 
Nodal receptor signaling in single cells.  
Compared with the Opto-acvr1b/2b system, the optoTGFβ system 
differentiates the two types of receptors: optoTβRI is attached to the plasma 
membrane, while optoTβRII is expressed in the cytoplasmic region and tagged 
with a fluorescent protein. On the one hand, the spatial separation of optoTβRI 
and optoTβRII could avoid a high level of basal TGFβ signaling before 
perturbation. On the other hand, as the subcellular localization of optoTβRII can 
be changed upon light irradiation, the optoTGFβ system is able to report the 
activities of the TGFβ receptors by visualizing the formation and dissociation of 
the receptors complexes. Therefore, compared with the design of the Opto-
acvr1b/2b system, our optoTGFβ system allows monitoring and charactering the 
dynamics of the TGFβ receptors, which would help to discover their quantitative 
relationships with the upstream signal input patterns, and with the various 
downstream responses in single cells. Since other branches of the TGFβ 
superfamily signaling (e.g. BMPs, Activin, GDFs, etc.) also employ the receptor-
multimerization strategy to initiate signaling, the optoTGFβ system could be 
easily generalized to these signaling pathways. 
Last but not least, due to the important roles of TGFβ signaling in various 
pathological processes, the optoTGFβ system is also a latent tool for medical 
application. Its spatiotemporal precision property makes optogenetics a 
promising and superior approach for targeted therapies. The earlier growth of 
photosensitive neuronal switches has promoted the evolvement of therapeutic 
strategies for in vivo manipulation with light294-300. In vivo perturbations of 
cellular behavior or metabolic activities have also been achieved in cells other 
than neurons301-304. Even clinical trials for a few optogenetic therapies have been 
launched in recent years305,306. All these strategies could be adopted for the in vivo 
application of the optoTGFβ system. For instance, gene delivery of optoTβRs to 
specific cells or tissues could be implemented by viral vectors or in vivo 
transfection such as PEI-mediated transfection. Multi-site, as well as 
customizable patterns of light stimulation could be delivered through 
implantable laser-coupled fiber optics or μLED probes. Cellular activities 
regulated by TGFβ signaling could thus be controlled, and the related signaling 
circuits could be logically rewired to achieve targeted therapy. Despite the 
present technical limitations, realistic perspectives are quickly emerging.  
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The multifunctional property of TGFβ signaling makes it an intriguing target 
for investigation. However, the lack of tools to control this pathway limits our 
understanding of it. In this thesis, we developed a light controllable TGFβ 
signaling system (the optoTGFβ system) by fusing light-sensitive proteins to the 
TGFβ receptors, and using fluorescence labeled Smad2 as the signaling indicator. 
After successfully establishing cell lines expressing the optoTGFβ system, we 
characterized it from various aspects, and compared it with the endogenous 
TGFβ signaling system. We found that the optoTGFβ system mimics the 
endogenous TGFβ signaling upon light stimulation, but has more flexibility 
through expanding the extent of signaling activation. In addition, we 
demonstrated the spatiotemporal controllability of the optoTGFβ system at the 
single cell level. By building a mathematical model on the optoTGFβ system, we 
not only better characterized it, but also equipped it with a computational tool for 
further investigation, and confirmed the dispensable role of endocytosis for Smad 
signaling. Altogether, the spatial and temporal precision of optical control allows 
the optoTGFβ system to work as not only a novel analytical tool for 
disentangling TGFβ signaling in various studies, but also a potential therapeutic 
tool for TGFβ signaling related diseases. 
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To generate the light-inducible TβRs system, we used the sequence encoding 
the photolyase homology region of cryptochrome 2 (PHR, amino acids 1-489) that 
was codon optimized for mammalian expression307, and the N-terminal part of 
CIB1 (CIBN, amino acid 1-147) from Arabidopsis thaliana170. The PCR-amplified 
sequence encoding CIBN was cloned into pmCerulean-C1 vector (Clontech), 
which resulted in a plasmid encoding CIBN-mCerulean. The myristoylation 
sequence of Lyn (amino acids 1-11) was added to the N-terminus of CIBN, and 
the cytoplasmic region of mouse TβRI (amino acids 148-502) was inserted 
between the myristoylation sequence and CIBN. To generate optoTβRI (Myr-
cytoTβRI-CIBN), the mCerulean sequence was deleted and blunted with Klenow 
enzyme. The optoTβRII (cytoTβRII-CRY2PHR-tdTomato) construct was 
generated by inserting sequence encoding PHR into the pmCitrine-C1 vector 
(Clontech). mCitrine was replaced with tdTomato and the cytoplasmic region of  
mouse TβRII (amino acids 190-567) was cloned into the N terminus of PHR. 
Finally, we generated a pLNCX2-optoTβRs plasmid by combining optoTβRI 
(Myr-cytoTβRI-CIBN) and optoTβRII (cytoTβRII-CRY2PHR-tdTomato) with 1:1 
ratio using a P2A bicistronic linker sequence (Figure 7.1.1 B). The piRFP682-N1 
plasmid was a gift from Vladislav Verkhusha (Addgene, #45459)223. To generate 
the iRFP682-C1 plasmid, the mCitrine sequence in the pmCitrine-C1 vector was 
replaced with the FP-encoding sequence from the piRFP682-N1 plasmid. For the 
construction of iRFP682-Smad2, cDNA encoding Smad2 was amplified and 
inserted to the piRFP682-C1 plasmid. The iRFP682-Smad2 was then amplified 
and replaced the EYFP-Smad2 of pREX-EYFP-Smad2-IRES-BSD (a gift from 
Xuedong Liu) to generate the pREX-iRFP682-Smad2-IRES-BSD for retroviral 
transfection (Figure 7.1.1 A). 
 
Figure 7.1.1 Brief maps for retroviral plasmids in this project.  (A) The 
plasmid encoding the iRFP682-Smad2 protein. (B) The plasmid of the optoTβRs proteins: 
Myr-cytoTβRI-CIBN (optoTβRI), cytoTβRII-CRY2PHR-tdTomato (optoTβRII). 
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 β
Hela cells (American Type Culture Collection) or  Human keratinocytes 
(HaCaT) were cultured in Dulbecco's Modified Eagle Medium (Lonza, Catalog 
#BE12-707F) or (GIBCO, Catalog #12800‐082), respectively, with 10% fetal bovine 
serum (Merck Biochrom, Catalog #S0615), 2 mM L-Glutamine (Gibco, Catalog 
#25030-024), 100 units/mL penicillin and 100 μg/mL streptomycin (Gibco, Catalog 
#15140-122) at 37°C and in 5% CO2.  
For handling cells expressing optoTβRs, ambient light should be avoided. All 
the operation steps were performed under red LED light (OSRAM). 
For TGFβ stimulation experiments, cells were seeded 24 h before treatment 
with TGF‐β1 (R&D Systems, 240‐B‐002). TβRs inhibitor LY364947 (Merck, 
Catalog #L6293) was added 2 hours before TGFβ treatment at a final 
concentration of 2.5 µM. 
For transfection experiments, cells were seeded one day before transfection. 
After incubation overnight, cells were transiently transfected using 
Lipofectamine 3000 (Invitrogen) following the manufacturer’s protocol. 
Transfected cells were incubated for at least 24 hours before experiments. 
 
 
We first generated cell lines stably expressing optoTβRI (Myr-cytoTβRI-CIBN) 
and optoTβRII (cytoTβRII-CRY2PHR-tdTomato) proteins. The packaging 
HEK293T cells were plated onto 60 mm dishes to be ~ 30% confluent at 
transfection. After 24 hours, the optoTβRs encoding plasmid pLNCX2- optoTβRs, 
as well as the pCL-Ampho Retrovirus packaging vector plasmid (a gift from 
Xuedong Liu) were co-transfected into the HEK293T cells using Lipofectamine 
3000 (Invitrogen, Catalog # L3000001) following the manufacturer’s protocol. 
Medium containing retroviral particles was filtered through a 0.45μm syringe 
filter (Carl Roth, Catalog #XH43.1) 48 hours after transfection. Viral supernatant 
was used immediately for retroviral transduction, or kept at −80 degrees for 
storage.  
For retroviral transduction, the filtered supernatant was mixed with a final 
concentration of 8μg/ml of Polybrene (Merck Chemicals, Catalog #TR-1003-G) 
before added to the target Hela or HaCaT cells (~ 30% confluency at transduction) 
in 100mm dishes. Infected cells were transferred to T75 flasks (Greiner bio-one, 
Catalog # 658175) upon confluent, and then either treated with corresponding 
antibiotics for 2 weeks until clonal isolation, or enriched for successfully 
transduced cells by FACS. The selected clonal cell line was confirmed by live cell 
imaging. We then generated the cell lines stably expressing both optoTβRs and 
iRFP682-Smad2 by stably transfecting the plasmid pREX-iRFP682-Smad2-IRES-
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BSD into the aforementioned cells (stably expressing optoTβRs) using a similar 
approach. 
 
 
Cultured cells were trypsinized and suspended in phenol-red free DMEM 
(Gibco, Catalog #31053‐028 and #11880-028 for HaCaT and Hela, respectively) at 
a concentration of ~ 1 million cells per 1 ml. All the samples were measured by 
BD FACS Aria II flow cytometer (BD Biocsiences, San Jose, USA). 561nm laser 
and 583/22-25 filter were used for tdTomato, 633nm laser and 670/14 filter were 
used for iRFP682. The data was analyzed by the FACSDivaTM software Version 
6.1.3. 
When sorting cells, Plasmocin TM Prophylactic (InvivoGen, Catalog #ant-mpp) 
was supplied at a final concentration of 5 μg/ml for the prevention of 
mycoplasma contamination. 
 
 
~1.5×106 cells were seeded in 60mm dishes (Greiner bio-one, Catalog # 628160) 
24 h before TGFβ stimulation or photoactivation in the LEDs illumination box. 
Samples were taken out of the incubator after indicated stimulation conditions 
and washed by ice-cold DPBS (Gibco, Catalog #14190‐094) twice before cell lysate 
preparation. 
Cells were lysed in RIPA buffer (Cell Signaling, Catalog #9806), supplemented 
with 1 mM PMSF, 1 mM NaF, protease inhibitor cocktail (Roche, Catalog #04 693 
132 001) and phosphatase inhibitor cocktail (Roche, Catalog #04 906 845 001). 
Protein concentrations were determined by using the Pierce BCA protein assay 
kit (Thermo Scientific, Catalog #23225) and a Infinite® F50 Absorbance 
Microplate Reader (Tecan Trading AG) according to the manufacturer's 
instructions. 
SDS–PAGE gels were transferred onto nitrocellulose membranes. The 
following primary antibodies were used in this work: Phospho-Smad2 
(Ser465/467) primary antibody (Cell Signaling, Catalog #3108) with a dilution of 
1:500, Smad2 primary antibody (Cell Signaling, Catalog #3103) with a dilution of 
1:1000, β-Actin primary antibody (Cell Signaling, Catalog #3700) with a dilution 
of 1:10000, optoTβRI primary antibody (Cell Signaling, Catalog #3712) with a 
dilution of 1:500, optoTβRII primary antibody (Santa Cruz, Catalog #sc-400) with 
a dilution of 1:200. All the primary antibodies were incubated overnight at 4°C. 
Secondary antibodies used for western blot were anti-rabbit IgG (H+L) DyLight 
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800 4X PEG Conjugate (Cell Signaling, Catalog #5151, dilution: 1:15000) and anti-
mouse IgG (H+L) DyLight 680 Conjugate (Cell Signaling, Catalog #5470, dilution: 
1:15000). Western blot images were acquired using the Odyssey CLx Imaging 
System (LI-COR Biosciences, Catalog # 9140) and the data was analyzed in the 
Image Studio Lite Ver 4.0. 
 
 
Cells were seeded in the µ-Slide 8 Well (ibidi, Catalog #80826) and incubated 
overnight. Samples were taken out of the incubator after indicated stimulation 
conditions and washed by DPBS (Gibco, Catalog #14190‐094) for three times 
followed by fixation in 4% PFA for 10 minutes. Permeabilization was performed 
with pre-chilled 100% methanol for 10 minutes after another DPBS washing 
(three times). Samples were blocked in PBS Fish Gel (ROCKLAND, Catalog #MB-
066-0100) overnight at 4°C. The primary antibody used in this work: Smad4 
primary antibody (SANTA CRUZ, Catalog # sc-7966) with a dilution of 1:100. The 
secondary antibodies used for immunofluorescence were the Anti-mouse IgG 
(H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) (Cell Signaling, Catalog # 
4408, dilution: 1:500). Images were acquired using a Plan-Apochromat 40 x/0.95 
Korr Ph 3 M27 objective (Zeiss, Catalog # 420661-9970) mounted on a Zeiss Axio-
Observer Z1 fluorescence microscope. The data was analyzed automatically in 
the free open-source software CellProfiler (Version 3.0.0)308. 
 
 
An illumination box with 475-nm LEDs (Roithner, Catalog #B56L5111P) was 
made according to a previous study309. The LEDs box was installed in a CO2 
incubator for illuminating live cells. The LED illumination power was measured 
with an optical power sensor (THORLABS, Catalog #S170C). 
To illuminate cells in the experiments for western blot assay, cell viability 
assays, RNA isolation and qPCR analysis, cells were seeded 24 h before being 
irradiated in the LEDs illumination box. The illumination power of LEDs in the 
box was adjusted to the specific value as indicated in the results. Samples were 
taken out at indicated time points after turning on the LEDs, and further 
processed for different experiments. 
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Cells were seeded in the µ-Slide 8 Well (ibidi, Catalog #80826) and incubated 
overnight. After replacing the medium with the phenol-red free DMEM, cells 
were ready for live cell imaging. 
Live cell imaging were performed using a Zeiss LSM 710 NLO 2-
photon/confocal laser scanning microscope, which was equipped with an 
incubator to maintain the samples at 37 °C and in 5% CO2. Images were captured 
using a Plan-Apochromat 63x/1.40 Oil DIC M27 objective (Zeiss, Catalog #420782-
9900). 
A 633nm laser with an intensity of 5.0 % was used for imaging both tdTomato 
and iRFP682. The detection wavelength (band-pass filter set) for collecting 
emission light of tdTomato was 638-759 nm, and for iRFP682 is 548-647 nm. 
Except indicated otherwise, images were normally taken at a frequency of 1 
image/min for the first 10 minutes following light stimulation (in order to capture 
the dynamics of optoTβRII), from then on, one image was captured every 10 
minutes. Other detailed information for imaging was listed in Figure 7.8.1. 
 
Figure 7.8.1  Information for imaging. A screenshot of the acquisition 
information in the ZEN software (Zeiss). Channel 1 and Channel 2correspond to iRFP682 
and tdTomato, respectively. 
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Cells expressing the optoTGFβ system were activated using an Argon laser at 
488nm with power 5.0 %, which results in an illumination power of 12.4 μW 
(measured by the optical power sensor on the focus plane). The illumination 
power could be adjusted by changing the scan speed to fine-tune the pixel dwell 
time.  
For 2-photom activation, a chameleon laser was used at power 5.0 %, and 
wavelength 860nm. 
 
 
Due to the lack of nuclear marker, automatic image quantification was hard to 
be implemented. Therefore, the live cell imaging data was manually quantified 
with ImageJ. The Smad2 signal was quantified as the ratio of nuclear-to-
cytoplasmic iRFP-Smad2 signal. Due to the difficulty of quantifying the 
fluorescence signal at the plasma membrane, the dynamics of optoTβRII were 
represented by the depletion of the cytoplasmic optoTβRII level. For comparison 
among different images, the mean tdTomato intensity (level of optoTβRII) in 
cytoplasmic area was normalized to that in the entire imaging field. Multiple 
corresponding areas were quantified and the average values were calculated.  
 
 
Cell viability tests were performed with Trypan blue staining and MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays. Cells were plated 
in 24-well plates (2.5×105 cells/well). After overnight incubation, cells were kept 
in dark or exposed to blue light (488 nm, 0.8 mW/cm2) in the LEDs illumination 
box for 24 hours. The percentages of viable cells were counted after Trypan blue 
staining in Bio-Rad TC20 cell counter according to the manufacturer's protocol. 
MTT assay was performed with the MTT reagent from SERVA (Catalog #20395) 
according to the manufacturer's instruction. The p-values were calculated using a 
two-sample t-test. 
 
 
~1.5×106 cells were seeded in 60mm dishes (greiner bio-one, Catalog # 628160) 
24 h before photoactivation in the LEDs illumination box. Samples were taken 
out of the incubator after indicated illumination time before extraction of RNA 
using the QIAGEN RNeasy Plus Mini Kit (QIAGEN, Catalog #74134), according 
to the manufacturer's protocol. The mRNAs from the samples were converted to 
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cDNAs using the QIAGEN QuantiTect Reverse Transcription Kit (QIAGEN, 
Catalog #205311), and the cDNAs were amplified with the QuantiFast SYBR 
Green PCR Kit (QIAGEN, Catalog #204054) in the StepOnePlus Real-Time PCR 
System from the Applied Biosystems. Data was normalized by the signal of 
GAPDH. The primer sets are listed as below (Table 7.11-1): 
 
Table 7.11-1 Sequences of the primers used in the study for qPCR 
Primers Sequence 
human GAPDH Forward CCACTCCTCCACCTTTGAC 
human GAPDH Reverse ACCCTGTTGCTGTAGCCA 
human SMAD7 Forward ACCCGATGGATTTTCTCAAACC 
human SMAD7 Reverse GCCAGATAATTCGTTCCCCCT 
human TMEPAI Forward GCACAGTGTCAGGCAACGG 
human TMEPAI Reverse AGATGGTGGGTGGCAGGTC 
human PAI1 Forward GAGACAGGCAGCTCGGATTC 
human PAI1 Reverse GGCCTCCCAAAGTGCATTAC 
 
 
The system of ordinary differential equations was prepared in the free 
software CellDesigner (Version 4.4)310. Model simulations, data fitting were 
implemented with SBML-PET-MPI242. Details of the mathematical modeling, 
including initial conditions, parameter values and the system of ordinary 
differential equations, were described in the chapter 5 (Developing a 
Mathematical Model for the optoTGFβ System).  
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